WO2003082871A1 - Imidazo fused compounds - Google Patents

Imidazo fused compounds Download PDF

Info

Publication number
WO2003082871A1
WO2003082871A1 PCT/EP2003/003178 EP0303178W WO03082871A1 WO 2003082871 A1 WO2003082871 A1 WO 2003082871A1 EP 0303178 W EP0303178 W EP 0303178W WO 03082871 A1 WO03082871 A1 WO 03082871A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
optionally
substituted
compound according
Prior art date
Application number
PCT/EP2003/003178
Other languages
French (fr)
Inventor
David Michael Goldstein
Ronald Charles Hawley
Alfred Sui-Ting Lui
Eric Brian Sjogren
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to CA002479644A priority Critical patent/CA2479644A1/en
Priority to MXPA04009585A priority patent/MXPA04009585A/en
Priority to AU2003215675A priority patent/AU2003215675B2/en
Priority to EP03745276A priority patent/EP1492790A1/en
Priority to JP2003580336A priority patent/JP2006503802A/en
Priority to KR1020047015609A priority patent/KR100656205B1/en
Priority to BR0308937-1A priority patent/BR0308937A/en
Publication of WO2003082871A1 publication Critical patent/WO2003082871A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Definitions

  • the present invention relates to certain heterocylic compounds as p38 protein kinase ("p38") inhibitors.
  • the present invention relates to imidazo-substituted hetero-bicyclic compounds, a process for their manufacture, pharmaceutical preparations comprising the same, and methods for using the same.
  • Mitogen-activated protein kinases is a family of proline-directed serine/threonine kinases that activate their substrates by dual phosphorylation.
  • the kinases are activated by a variety of signals including nutritional and osmotic stress, UV light, growth factors, endotoxin and inflammatory cytokines.
  • One group of MAP kinases is the p38 kinase group which includes various isoforms (e.g., p38 ⁇ , p38 ⁇ , p38 ⁇ and p38 ⁇ ).
  • the p38 kinases are responsible for phosphorylating and activating transcription factors as well as other kinases, and are themselves activated by physical and chemical stress, pro-inflammatory cytokines and bacterial lipopolysaccharide.
  • TNF- ⁇ is a cytokine produced primarily by activated monocytes and macrophages. Its excessive or unregulated production has been implicated as playing a causative role in the pathogenesis of rheumatoid arthritis. More recently, inhibition of TNF production has been shown to have broad application in the treatment of inflammation, inflammatory bowel disease, Alzheimer's disease, Crohn's disease, multiple sclerosis and asthma.
  • TNF has also been implicated in viral infections, such as HIV, influenza virus, and herpes virus including herpes simplex virus type-1 (HSN-1), herpes simplex virus type-2 (HSV-2), cytomegalo virus (CMN), varicella-zoster virus (VZV), Epstein-Barr virus, human herpes virus-6 (HHV-6), human herpesvirus-7 (HHV-7), human herpesvirus-8 (HHN-8), pseudorabies and rhinotracheitis, among others.
  • HSN-1 herpes simplex virus type-1
  • HSV-2 herpes simplex virus type-2
  • CPN cytomegalo virus
  • VZV varicella-zoster virus
  • Epstein-Barr virus Epstein-Barr virus
  • HHV-6 human herpes virus-6
  • HHV-7 human herpesvirus-7
  • HHN-8 human herpesvirus-8
  • pseudorabies and rhinotracheitis among others.
  • IL-1 is produced by activated monocytes and macrophages, and plays a role in many pathophysiological responses including rheumatoid arthritis, fever and reduction of bone resorption.
  • the present invention provides compounds represented by the formula I:
  • Z 1 is selected from ⁇ and CH when the bond between atoms C5 and Z 1 is a single bond, and Z 1 is C when the bond between C5 and Z 1 is a double bond;
  • R 1 is hydrogen or alkyl;
  • R- is alkyl, aralkyl, cycloalkyl, heteroalkyl, heterocyclyl, aryl, or heteroaryl;
  • R' is hydrogen or alkyl
  • R 3 is hydrogen, alkyl, aryl, heteroaryl, or cycloalkyl
  • the bond between atoms C5 and Z 1 is a single or double bond
  • the bond between atoms C8 and C9 is a single or double bond
  • Y is an alkyl, heteroalkyl, cycloalkyl, aryl, or heteroaryl; or isomers, pharmaceutically acceptable salts, esters or prodrugs thereof.
  • Y is phenyl optionally substituted with one to two groups selected from halo, hydroxy, amino, alkyl or heteroalkyl; or isomers, pharmaceutically acceptable salts, esters or prodrugs thereof; or
  • R is selected from cyclopentyl, cyclohexyl, tetrahydropyranyl, piperidinyl, thianonyl, tetrahydro-l,l-dioxide-2-H- thiopyranyl, phenyl, and benzyl, wherein each of said R groups is optionally substituted with one of hydroxy, halogen, O(C ⁇ - 4 alkyl), or S(O) (C ⁇ - 4 alkyl); or R .2 is selected from C ⁇ - 4 alkyl optionally substituted with one of hydroxy, O(C ⁇ - 4 alkyl) or S(O) 2 (C 1 - 4 alkyl); or
  • R is selected from cyclopentyl, cyclohexyl, tetrahydropyranyl, piperidinyl, thianonyl, tetrahydro-l,l-dioxide-2-H- thiopyranyl, phenyl, and benzyl, wherein each of said R groups is optionally- substituted with one of hydroxy, halogen, O(CH 3 ), or S(O) 2 (CH 3 ); or R 2 is selected from C ⁇ - 4 alkyl optionally substituted with one of hydroxy, O(CH 3 ) or S(O) 2 (CH 3 ); or
  • R is selected from cyclopentyl, cyclohexyl, tetrahydropyranyl, piperidinyl, thianonyl, tetrahydro- l,l-dioxide-2-H-thiopyranyl, phenyl, and benzyl, wherein each of said R 2 groups is optionally-substituted with one of hydroxy, halogen, O(C ⁇ . 4 alkyl), or S(O) 2 (C ⁇ . - 4 alkyl); or R 2 is selected from C ⁇ - 4 alkyl optionally substituted with one of hydroxy, O(C ⁇ - 4 alkyl) or S(O) 2 (C ⁇ - 4 alkyl); or
  • A is absent or O
  • R 1 is hydrogen
  • R is alkyl, hydroxyalkyl, optionally-substituted cycloalkyl, optionally-substituted heteocyclyl, optionally-substituted aryl, or optionally-substituted aralkyl; and the bond between C8 and C9 is a single or double bond; or
  • R is 4-tetrahydropyranyl and Y is 4-fluorophenyl;
  • R 2 is 4-fluorophenyl and Y is 4-fluorophenyl;
  • R 2 is 4-hydroxycyclohexyl and Y is 2-chlorophenyl;
  • R 2 is 4-tetrahydropyranyl and Y is 2-chlorophenyl;
  • R 2 is 4-(N-methyl-sulfonylpiperdinyl) and Y is 2-chlorophenyl;
  • R 2 is cyclopentyl and Y is 2-chlorophenyl
  • R 2 is 4-(N-methyl-sulfonylpiperdinyl) and Y is 2-chlorophenyl;
  • R 2 is 4-tetrahydro,l,l-dioxide-2-H-thiopyranyl and Y is 2-chlorophenyl; R 2 is isopropyl and Y is 2-chlorophenyl; or
  • R 2 is 4-fluorbenzyl and Y is 2-chlorophenyl;
  • the compounds of formula I and their aforementioned salts are inhibitors of protein kinases and exhibit effective activity against p38 in vivo. Therefore, the compounds can be used for the treatment of diseases mediated by the pro- inflammatory cytokines such as TNF and IL-1.
  • the present invention relates to methods for the treatment of p38 mediated diseases or conditions in which a therapeutically effective amount of a compound of formula I is administered to a patient in need of such treatment.
  • the present invention relates to methods for preparing the compounds described above.
  • the present invention relates to methods for preparing medicaments useful for the treatment of the p38 mediated diseases and conditions.
  • alkyl means a linear saturated monovalent hydrocarbon radical or a branched saturated monovalent hydrocarbon radical of one to six carbon atoms, e.g., methyl, ethyl, n-propyl, 2-propyl, tert-butyl, pentyl, and the like.
  • aryl refers to a monovalent monocyclic or bicyclic aromatic hydrocarbon radical preferably phenyl which is optionally substituted independently with one or more substituents.
  • the substituents are preferably selected from the group consisting of alkyl, haloalkyl, halo, hydroxy, nitro, cyano, amino, haloalkoxy, heteroalkyl, methylenedioxy, ethylenedioxy, Y-aryl, Y- heteroaryl, Y-cycloalkyl, Y-heterocyclyl, Y-OR p -Y-NR p R q , -Y-C(O)-R p , -YS(O) 0 -2R P .
  • aryl includes, but is not limited to, phenyl, chlorophenyl, methoxyphenyl, 1-naphthyl, 2-naphthyl, and the derivatives thereof.
  • Alkyl means a radical -R x R y where R x is an alkylene group and R is an aryl group as defined above, e.g. benzyl, phenylethylene, and the like.
  • cycloalkyl refers to a saturated monovalent cyclic hydrocarbon radical of three to seven ring carbons, e.g., cyclopentyl, cyclobutyl, cyclohexyl, and the like.
  • the saturated monovalent cyclic hydrocarbon radical as defined above may be optionally substituted with one, two or three substituents which are not hydrogen.
  • the substituents are selected from the group consisting of alkyl, hydroxy, alkoxy, amino, monosubstituted amino, disubstituted amino, haloalkyl, halo, cyanoalkyl, oxo (i.e., carbonyl oxygen), heteroalkyl, heterocyclyl, hydroxyalkyl, and -(X) n -C(O)R' (where, X is O or NR", n is 0 or 1, R" is hydrogen, alkyl, haloalkyl, amino, monosubstituted amino, disubstituted amino, hydroxy, alkoxy, alkyl or optionally substituted phenyl, and R' is H or alkyl), and -S(O) n R' (wherein n is 0 to 2). More specifically, the term substituted cycloalkyl includes, for example, substituted cyclopentyl, substituted cyclohexyl, and the like.
  • halo when referring to a substituent means fluoro, chloro, bromo, or iodo, preferably chloro.
  • haloalkyl means alkyl substituted with one or more same or different halo atoms, e.g., -CH2CI, -CF3, -CH2CF3, -CH2CCI3, and the like, and further includes those alkyl groups such as perfluoroalkyl in which all alkyl hydrogen atoms are replaced by fluorine atoms.
  • heteroalkyl as used herein means an alkyl radical defined above, wherein one, two or three hydrogen atoms have been replaced with a substituent independently selected from the group consisting of -OR a , -NR b R c , and S(O) n R d (where n is an integer from 0 to 2), with the understanding that the point of attachment of the heteroradical is through a carbon atom, wherein R a is hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylalkyl; or R b and R c are independently of each other hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylakyl, or R b and R c together with the nitrogen atom to which they are attached form heterocyclo or heteroaryl; and when n is 0, R d is hydrogen, alkyl, cycloalkyl, or cycloalkylakyl, and when n is 1 or 2, R
  • Representative examples include, but are not limited to, 2- hydroxyethyl, 3-hydroxypropyl, 2-hydroxymethylethyl, 2,3-dihydroxypropyl, 1-hydroxy-methylethyl, 3-hydroxybutyl, 2,3-dihydroxybutyl, 2-hydroxy-l- methylpropyl, 2-aminoethyl, 3-aminopropyl, 2-methylsulfonylethyl, aminosulfonylmethyl, aminosulfonylethyl, methylaminosulfonylmethyl, methylaminosulfonylethyl, methylaminosulfonylpropyl, and the like.
  • R a is hydrogen
  • the radical -OR a is also referred to as "hydroxyalkyl" and includes, but is not limited to, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxymethylethyl,
  • Heteroaryl means a monvalent monocyclic or bicyclic radical of 5 to 12 ring atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, with the understanding that when the heteroaryl is a bicyclic system in which one of the rings is carbocyclic and/or non-aromatic, the attachment point of the heteroaryl radical will be on a heteroaryl ring.
  • the heteroaryl ring is optionally substituted with one or more substituents, preferably one or two substituents, independently from each other selected from alkyl, haloalkyl, halo, nitro, cyano, amino, methylenedioxy, Y-aryl, Y-heteroaryl, Y-cycloalkyl, -Y-heterocyclyl, -Y-OR', -YNR'R", -Y-C(O)R ⁇ -Y-O-C(O)-R', -Y-S(O) 0 - 2 -R ⁇ -Y-N-SO 2 -R', -Y-SO 2 - NR'R", and -Y-N-C(O)-NR'R", where Y is absent or a C ⁇ -C 3 alkylene group and R' and R" are each independently from each other hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, aryl, heteroaryl,
  • heteroaryl includes, but is not limited to, pyridyl, furanyl, thienyl, thiazolyl, isothiazolyl, triazolyl, imidazolyl, isoxazolyl, pyrrolyl, pyrazolyl, pyrimidinyl, benzofuranyl, tetrahydrobenzofuranyl, isobenzofuranyl, benzo- thiazolyl, benzoiosthiazolyl, benzotriazolyl, indolyl, isoindolyl, benzoxazolyl, quinolyl, tetrahydroquinolnyl, isoquinolyl, benzimidazolyl, benzisoxazolyl or benzothienyl, imidazo[l,2-a]-pryidinyl, imidazo[2,l-b]thiazolyl, and derivatives thereof.
  • “Monosubstituted amino” means a radical -NHR e where R e is alkyl, heteroalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heterocyclyl, or heterocyclylalkyl, e.g., methylamino, ethylamino, phenylamine, benzylamine, and the like.
  • disubstituted amino refers to a radical -NR g R h wherein R s and R h are, independently of each other, alkyl, heteroalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heterocyclyl, or heterocyclylalkyl, or R g and R h together with the nitrogen atom to which they are attached form a heterocyclyl ring.
  • Representative examples include, but are not limited to, dimethylamino, methylethylamino, di(l-methyl-ethyl)amino, piperazinyl, and the like.
  • the heterocyclyl ring may be optionally substituted independently with one, two, or three substituents selected from alkyl, hydroxy, hydroxyalkyl, alkoxy, heteroalkyl, haloalkyl, and -(X) n -C(O)R (where, X is O or NR', n is 0 or 1, R is hydrogen, alkyl, haloalkyl, amino, monosubstituted amino, disubstituted amino, hydroxy, alkoxy, or optionally-substituted phenyl, and R' is H or alkyl), Y-aryl, Y-heteroaryl, Y-cycloalkyl, Y-heterocyclyl, Y-OR p , -Y- NR p R q , -Y-C(O)-R p , -YS(O)o_2R p .
  • Y is absent or a C ⁇ -C 3 alkylene group
  • R p and R q are each independently from each other selected from hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, aryl, heteroaryl, cycloalkyl, and heterocyclyl.
  • heterocyclyl includes, but is not limited to, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, and the derivatives thereof.
  • acyl refers to the group -C(O)R r where R r is alkyl, haloalkyl, heteroalkyl, aryl, heteroaryl, aralkyl or heteroaralkyl.
  • Alkoxy means a radical - OR where R is an alkyl, aryl, aralkyl, or heteroaralkyl, respectively, as defined above, e.g., methoxy, phenoxy, pyridin-2-ylmethyloxy, benzyloxy, and the like.
  • R is an alkyl, aryl, aralkyl, or heteroaralkyl, respectively, as defined above, e.g., methoxy, phenoxy, pyridin-2-ylmethyloxy, benzyloxy, and the like.
  • the two bonds appears as a dotted line, as in , it should be understood that unless otherwise specifically stated, this notation means the bond optionally may be a single bond or a double bond, with appropriate selections being made for adjacent atoms.
  • the dotted line is a bond
  • the dotted line is not a bond
  • Leaving group has the meaning conventionally associated with it in synthetic organic chemistry, i.e., an atom or a group capable of being displaced by a nucleophile and includes halo (such as chloro, bromo, and iodo), alkanesulfonyloxy, arenesulfonyloxy, alkylcarbonyloxy (e.g., acetoxy), arylcarbonyloxy, mesyloxy, tosyloxy, trifluoromethanesulfonyloxy, aryloxy (e.g., 2,4-dinitrophenoxy), methoxy, N-O-dimethylhydroxylamino, and the like.
  • halo such as chloro, bromo, and iodo
  • alkanesulfonyloxy arenesulfonyloxy
  • alkylcarbonyloxy e.g., acetoxy
  • arylcarbonyloxy mesyloxy, tosyloxy
  • “Pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use.
  • a "pharmaceutically acceptable excipient” as used in the specification and claims includes both one and more than one such excipient.
  • “Pharmaceutically acceptable salt” of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
  • Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2- ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulf
  • prodrug and “prodrug” are used interchangeably herein and refer to any compound which releases an active parent drug according to Formula I in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs of a compound of Formula I are prepared by modifying one or more functional group(s) present in the compound of Formula I in such a way that the modification(s) may be cleaved in vivo to release the parent compound.
  • Prodrugs include compounds of Formula I wherein a hydroxy, amino, or sulfhydryl group in a compound of Formula I is bonded to any group that may be cleaved in vivo to regenerate the free hydroxyl, amino, or sulfhydryl group, respectively.
  • prodrugs include, but are not limited to, esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups in compounds of Formula I, and the like.
  • esters e.g., acetate, formate, and benzoate derivatives
  • carbamates e.g., N,N-dimethylaminocarbonyl
  • Protecting group refers to a grouping of atoms that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in T.W. Green and P.G. Futs, Protective Groups in Organic Chemistry, (Wiley, 2 nd ed. 1991) and Harrison and Harrison et al., Compendium of Synthetic Organic Methods, Nols. 1-8 (John Wiley and Sons, 1971-1996).
  • Representative amino protecting groups include, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (CBZ), tert-butoxycarbonyl (Boc), trimethyl silyl (TMS), 2-trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (FMOC), nitro- veratryloxycarbonyl (NVOC), and the like.
  • hydroxy protecting groups include those where the hydroxy group is either acylated or alkylated such as benzyl, and trityl ethers as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers and allyl ethers.
  • Treating" or “treatment” of a disease includes: (1) preventing the disease, i.e., causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease; (2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or (3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms.
  • a therapeutically effective amount means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
  • the present invention provides compounds represented by the formula:
  • Preferred compounds of formula I includee those wherein A is absent or - O-, both Z and Z 1 are N, Y is an aryl, R 1 is hydrogen, and R 2 is as defined above for compounds of formula (I). More preferred compounds are compounds of formula I, wherein Z is N, Z 1 is C such that the bond between C5 and Z 1 is a double bond, A is absent or -O, Y is aryl (more preferably optionally-substituted phenyl), R is hydrogen, and R is as defined above for compounds of formula I. Still more preferred compounds are compounds of formula 1(a):
  • Z is N, A or absent or -O-, Y is optionally-substituted phenyl, R 1 is hydrogen, and R 2 is as defined above.
  • Most preferred compounds are those of formula 1(a) wherein Z is N, A is absent, Y is a phenyl substituted with a halo, hydroxy, amino, alkyl or heteroalkyl, R 1 is hydrogen, and R 2 is alkyl, heteroalkyl, optionally-substituted cycloalkyl, optionally-substituted heterocycyl or substituted phenyl or benzyl.
  • Particularly preferred compounds are compounds of formula 1(a) wherein A is absent, Y is phenyl substituted with a halo, the dotted line is a double bond, R 1 is hydrogen, and R is alkyl (more preferably lower alkyl optionally substituted with hydroxy, methoxy or methylsulfonyl), heteroalkyl, optionally-substituted cycloalkyl (more preferably cyclopentyl or cyclohexyl optionally substituted with methoxy), optionally-substituted heterocycyl (more preferably optionally- substituted piperidinyl), or substituted phenyl or benzyl (more preferably phenyl or benzyl substituted with a halo).
  • Table I lists some of the representative compounds of formula 1(a).
  • a preferred compound (12) of formula 1(c) is wherein Z is N, A is absent, R is hydrogen, Y is 2-chlorophenyl, and R is 4-hydroxycyclohexyl. Mass spectra of MH+ 399.
  • Representative compounds of formula 1(a) are compounds wherein the dotted line is a bond, Z is N, R 1 is hydrogen, and the values of R 2 , A, and Y are as set forth below:
  • a preferred compound (13) of formula 1(a) is a compound wherein Z is N, the dotted line is not a bond, R 1 is hydrogen, R 2 is 4-hydroxycylcohexyl, and Y is 2-chlorophenyl. MH+ 396, M.P. 169.3°C to 175.8°C.
  • Particularly preferred compounds of formula 1(a) are compounds (3) and (7) of Table 1, above.
  • the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms and are intended to be encompassed within the scope of the invention. Furthermore, as stated above, the present invention also includes all pharmaceutically acceptable salts of the compounds along with prodrug forms of the compounds and all stereoisomers whether in a pure chiral form or a racemic mixture of other forms of mixture.
  • the compounds of formula I are capable of further forming pharmaceutically acceptable acid addition salts. All of these forms are also contemplated within the scope of the claimed invention.
  • Pharmaceutically acceptable acid addition salts of the compounds of formula I include salts derived from inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, phosphorus, and the like, as well as the salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.
  • Such salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydro- genphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, pthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartarate, methane- sulfonate, and the like.
  • salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge et al., "Pharmaceutical Salts," J. of Pharmaceutical Science, 1977, 66, 1-19).
  • the acid addition salts of the basic compounds can be prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner.
  • the free base form can be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner.
  • the free base forms may differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for the purposes of the present invention.
  • Pharmaceutically acceptable base addition salts can be formed with metal ions or amines, such as alkali and alkaline earth metal ions or organic amines.
  • metal ions which are used as cations include sodium, potassium, magnesium, calcium, and the like.
  • suitable amines are N, N'- dibenzylethylenediamine, chlororocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., supra).
  • the basic addition salts of acidic compounds can be prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner.
  • the free acid form can be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner.
  • the free acid forms may differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for the purposes of the present invention.
  • the compounds of the present invention can be prepared by a variety of methods, using procedures well-known to those of skill in the art.
  • NMP l-methyl-2-pyrrolidinone.
  • THF tetrahydrofuran.
  • LAH lithium aluminum hydride
  • DMF dimethylformamide DMPU: l,3-dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidinone
  • Scheme 1 describes a general method of synthesizing compounds of formula 1(a) (1) (compounds of formula 1(a) wherein the dotted line is not a bond) starting with a protected thiopyridine-5-carboxylate 1, wherein R p and R pa are protecting groups such as lower alkyl and benzyl; and R L is a leaving group such as a halo.
  • the protecting and leaving groups are as defined on page 6, lines 30 through page 7, line 9 and page 5, lines 22-26, respectively.
  • the general method of preparing compound 5 from carboxlyate 1 in the Scheme is described in WO 0129042 and WO 0129041.
  • Compound 1 is treated with triethylamine and aqueous ammonium to afford compound 2.
  • Compound 2 is reduced with lithium aluminum hydride or other reducing agents well known in the art to yield compound 3.
  • Compound 3 is oxidized to aldehyde 4 by treating it with activated manganese oxide powder or by other oxidizing methods known in the art.
  • Compound 4_ is reacted with an ester of general formula -A-Y-C(O)OR z , wherein A and Y are as defined above and R z is lower alkyl, aryl or cycloalkyl, to afford pyrimidinone 5.
  • Tricyclic sulfide 8 may be directly reacted with an amine of the general formula -NH R R to afford a compound of general formula 1(a)(1).
  • Scheme 2 describes a general method of preparing a compound of formula 1(a)(2) (compounds of formula 1(a) wherein the dotted line is a bond), by starting with the aldehyde 4 from Scheme 1 above and heating it with a cyanide of general formula CN-CH 2 -A-Y, wherein A and Y are as defined above, and potassium carbonate in DPMU to obtain aminopyridopyrimidine 9.
  • Compound 9 is treated with triethylamine and 1,2-dichloroethyl ethyl ether to afford sulfide of formula 10.
  • Scheme 3 describes a general method of preparing compound of formula 1(c) starting with compound 12.
  • Compound 12 is prepared according to the method described in WO 0129042 and WO 0129041.
  • Compound Y2 is treated with triphenylphosphine, diethylazodicarboxylate and N- (2-hydroxyethyl)-phthalimide to obtain compound 13.
  • Compound 13 is then reacted with hydrazine hydrate to obtain compound 14, which is then reacted with trimethylaluminum solution to obtain compound 15.
  • Compound 15 is reacted with an amine of formula -H 2 NR R to obtain a compound of formula 1(c).
  • compound 15 can be oxidized with 3-chloroperbenzoic acid to obtain the corresponding sulfoxide (not shown) which is then reacted with amine -NR ! R 2 to obtain the desired compound of formula I (c).
  • a process of making a compound according to Claim 1, comprising: reacting a compound of formula A with a cyanide of formula CN-CH 2 -A-Y wherein A, Z and Y are as defined in Claim 1, and R p is selected from lower alkyl and benzyl, to afford a compound of formula B;
  • a process of preparing a compound according to Claim 1 comprising: a) reacting a compound of formula E wherein Z, A and Y are as defined in Claim 1 and R p is lower alkyl or benzyl, with a reagent selected from triphenylphosphine, diethylazodicarboxylate, and N-(2-hydroxyethyl)-phthalimide to obtain compound F;
  • a reagent selected from 3- chloroperbenzoic acid, hydrogen peroxide/formic acid, hydrogen peroxide/ methyltrioxorhenium VII, or OXONE
  • the compounds of formula I and the pharmaceutically acceptable salts of basic compounds of formula I with acids can be used as medicaments, e.g. in the form of pharmaceutical preparations.
  • the pharmaceutical preparations can be administered enterally, e.g. orally in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, nasally, e.g. in the form of nasal sprays, or rectally, e.g. in the form of suppositories. However, they may also be administered parenterally, e.g. in the form of injection solutions.
  • the compounds of formula I and their aforementioned pharmaceutically acceptable salts can be processed with pharmaceutically inert, organic or inorganic carriers for the production of pharmaceutical preparations.
  • Lactose, com starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active ingredient no carriers are, however, usually required in the case of soft gelatine capsules.
  • Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like.
  • Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • the pharmaceutical preparations can also contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain therapeutically valuable substances other than the compounds of formula I and their aforementioned pharmaceutically acceptable salts.
  • Medicaments which contain a compound of formula I or a pharmaceutically acceptable salt of a basic compound of formula I with an acid in association with a compatible pharmaceutical carrier material are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more of these compounds or salts and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with a compatible pharmaceutical carrier.
  • the compounds of formula I and their aforementioned pharmaceutically acceptable salts can be used in accordance with the invention as therapeutically active substances, especially as antiinflammatory agents or for the prevention of graft rejection following transplant surgery.
  • the dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of administration to adults a convenient daily dosage should be about 0.1 mg/kg to about 100 mg/kg, preferably about 0.5 mg/kg to about 5 mg/kg.
  • the daily dosage may be administered as a single dose or in divided doses and, in addition, the upper dosage limit referred to earlier may be exceeded when this is found to be indicated.
  • the present invention provides a method of treating a cytokine-mediated disease which comprises administering an effective cytokine- interfering amount of a compound of Formula I, or a pharmaceutically acceptable salt or tautomer thereof.
  • Compounds of Formula I would be useful for, but not limited to, the treatment of inflammation in a subject, and for use as antipyretics for the treatment of fever.
  • Compounds of the invention would be useful to treat arthritis, including but not limited to, rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, and other arthritic conditions.
  • Such compounds would be useful for the treatment of pulmonary disorders or lung inflammation, including adult respiratory distress syndrome, pulmonary sarcoidosis, asthma, silicosis, and chronic pulmonary inflammatory disease.
  • the compounds are also useful for the treatment of viral and bacterial infections, including sepsis, septic shock, gram negative sepsis, malaria, meningitis, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), pneumonia, and herpes virus.
  • the compounds are also useful for the treatment of bone resorption diseases, such as osteoporosis, endotoxic shock, toxic shock syndrome, reperfusion injury, autoimmune disease including graft vs.
  • cardiovascular diseases including atherosclerosis, thrombosis, congestive heart failure, and cardiac reperfusion injury, renal reperfusion injury, liver disease and nephritis, and myalgias due to infection.
  • the compounds are also useful for the treatment of influenza, multiple sclerosis, cancer, diabetes, systemic lupus erthrematosis (SLE), skin-related conditions such as psoriasis, eczema, burns, dermatitis, keloid formation, and scar tissue formation.
  • Compounds of the invention also would be useful to treat gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis.
  • the compounds would also be useful in the treatment of ophthalmic diseases, such as retinitis, retinopathies, uveitis, ocular photophobia, and of acute injury to the eye tissue.
  • Compounds of the invention also would be useful for treatment of angiogenesis, including neoplasia; metastasis; ophthalmological conditions such as corneal graft rejection, ocular neovascularization, retinal neovascularization including neovascularization following injury or infection, diabetic retinopathy, retrolental fibroplasia and neovascular glaucoma; ulcerative diseases such as gastric ulcer; pathological, but non-malignant, conditions such as hemangiomas, including infantile hemangiomas, angiofibroma of the nasopharynx and avascular necrosis of bone; diabetic nephropathy and cardiomyopathy; and disorders of the female reproductive system such as endometriosis.
  • the compounds of the invention may also
  • these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.
  • the present compounds may also be used in co-therapies, partially or completely, in place of other conventional antiinflammatories, such as together with steroids, cyclooxygenase-2 inhibitors, NSAIDs, DMARDS, immunosuppressive agents, 5-lipoxygenase inhibitors, LTB 4 antagonists and LTA 4 hydrolase inhibitors.
  • TNF mediated disorder refers to any and all disorders and disease states in which TNF plays a role, either by control of TNF itself, or by TNF causing another monokine to be released, such as but not limited to IL-1, IL-6 or IL-8.
  • TNF a disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore be considered a disorder mediated by TNF.
  • p38 mediated disorder refers to any and all disorders and disease states in which p38 plays a role, either by control of p38 itself, or by p38 causing another factor to be released, such as but not limited to IL- 1, IL-6 or IL-8.
  • IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to p38, would therefore be considered a disorder mediated by p38.
  • TNF- ⁇ has close structural homology with TNF- ⁇ (also known as cachectin), and since each induces similar biologic responses and binds to the same cellular receptor, the synthesis of both TNF- ⁇ and TNF- ⁇ are inhibited by the compounds of the present invention and thus are herein referred to collectively as "TNF” unless specifically delineated otherwise.
  • a glass sealed-tube (teflon screw cap) reactor was charged with 0.4 g (1.2 mmol) of the sulfoxide 10. This was purged with nitrogen for 2 minutes as the reaction vessel was cooled with an ice-water bath. 5 ml of isopropyl amine was added and the tube was sealed. The red solution was heated in a 64°C oil bath for 2 hours until reaction was completed. The mixture was cooled and the reaction vessel was rinsed with dichloromethane. The solvent was removed in vacuo and the sample was purified by column chromatography with silica eluting with a gradient of 5 to 10% ethyl acetate in dichloromethane affording 0.34 g (87% yield) of product.
  • Example 13 The following are representative pharmaceutical formulations containing a compound of Formula (I).
  • Tablet formulation The following ingredients are mixed intimately and pressed into single scored tablets.
  • Capsule formulation The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.
  • Quantity per Ingredient capsule mg compound of this invention 200 lactose, spray-dried 148 magnesium stearate 2 Suspension formulation The following ingredients are mixed to form a suspension for oral administration.
  • Ingredient Amount compound of this invention 1.0 g fumaric acid 0.5 g sodium chloride 2.0 g methyl paraben 0.15 g propyl paraben 0.05 g granulated sugar 25.5 g Sorbitol (70% solution) 12.85 g
  • Veegum K (Vanderbilt Co.) 1.0 g flavoring 0.035 ml colorings 0.5 mg distilled water q.s. to 100 ml
  • Injectable formulation The following ingredients are mixed to form an injectable formulation.
  • Suppository formulation A suppository of total weight 2.5 g is prepared by mixing the compound of the invention with Witepsol® H-15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:
  • the p-38 MAP kinase inhibitory activity of compounds of this invention in vitro was determined by measuring the transfer of the ⁇ -phosphate from ⁇ - P- ATP by p-38 kinase to Myelin Basic Protein (MBP), using the a minor modification of the method described in Ahn, N. G.; et al. J. of Biol. Chem. Vol. 266(7), 4220- 4227, (1991)
  • the phosphorylated form of the recombinant p38 MAP kinase was expressed with SEK-1 and MEK-K in E. Coli (see, Khokhlatchev, A. et al. J. of Biol. Chem. Vol. 272(17), 11057-11062, (1997) and then purified by affinity chromatography using a Nickel column.
  • the phosphorylated p38 MAP kinase was diluted in kinase buffer (20 mM
  • the reaction was terminated by adding 0.75% phosphoric acid.
  • the phosphorylated MBP was then separated from the residual ⁇ - 33 P-ATP using a phosphocellulose membrane (Millipore, Bedfrod, MA) and quantitated using a scintillation counter (Packard, Meriden, CT).
  • IC 50 the concentration causing 50% inhibition of the p-38 enzyme being analyzed
  • Table 2 shows representative values for inhibition of p38 using the Ex. 14 assay:

Abstract

The present invention discloses compounds corresponding to formula (I): wherein A, Z, Z1, Y, R1 and R2 are as defined in the specification, as well as pharmaceutical formulations, methods of making and uses thereof for the treatment of p38 mediated diseases.

Description

IMIDAZO FUSED COMPOUNDS
The present invention relates to certain heterocylic compounds as p38 protein kinase ("p38") inhibitors. In particular, the present invention relates to imidazo-substituted hetero-bicyclic compounds, a process for their manufacture, pharmaceutical preparations comprising the same, and methods for using the same.
Mitogen-activated protein kinases (MAP) is a family of proline-directed serine/threonine kinases that activate their substrates by dual phosphorylation. The kinases are activated by a variety of signals including nutritional and osmotic stress, UV light, growth factors, endotoxin and inflammatory cytokines. One group of MAP kinases is the p38 kinase group which includes various isoforms (e.g., p38α, p38β, p38 δ and p38γ). The p38 kinases are responsible for phosphorylating and activating transcription factors as well as other kinases, and are themselves activated by physical and chemical stress, pro-inflammatory cytokines and bacterial lipopolysaccharide.
More importantly, the products of the p38 phosphorylation have been shown to mediate the production of inflammatory cytokines, including TN , IL-1, IL-6 and cyclooxygenase-2. Each of these cytokines has been implicated in numerous disease states and conditions. For example, TNF-α is a cytokine produced primarily by activated monocytes and macrophages. Its excessive or unregulated production has been implicated as playing a causative role in the pathogenesis of rheumatoid arthritis. More recently, inhibition of TNF production has been shown to have broad application in the treatment of inflammation, inflammatory bowel disease, Alzheimer's disease, Crohn's disease, multiple sclerosis and asthma.
TNF has also been implicated in viral infections, such as HIV, influenza virus, and herpes virus including herpes simplex virus type-1 (HSN-1), herpes simplex virus type-2 (HSV-2), cytomegalo virus (CMN), varicella-zoster virus (VZV), Epstein-Barr virus, human herpes virus-6 (HHV-6), human herpesvirus-7 (HHV-7), human herpesvirus-8 (HHN-8), pseudorabies and rhinotracheitis, among others.
Similarly, IL-1 is produced by activated monocytes and macrophages, and plays a role in many pathophysiological responses including rheumatoid arthritis, fever and reduction of bone resorption.
The inhibition of these cytokines by inhibition of the p38 kinase is of benefit in controlling, reducing and alleviating many of these disease states.
In one aspect (i), the present invention provides compounds represented by the formula I:
Figure imgf000003_0001
(I) wherein: Z is Ν or CH;
Z1 is selected from Ν and CH when the bond between atoms C5 and Z1 is a single bond, and Z1 is C when the bond between C5 and Z1 is a double bond; R1 is hydrogen or alkyl;
R- is alkyl, aralkyl, cycloalkyl, heteroalkyl, heterocyclyl, aryl, or heteroaryl; A is absent or -O-, -CHR'-, -C(=O)-, -S(O)„- or -ΝR3~, wherein n is 0,
1, or 2, R' is hydrogen or alkyl, and R3 is hydrogen, alkyl, aryl, heteroaryl, or cycloalkyl; the bond between atoms C5 and Z1 is a single or double bond; the bond between atoms C8 and C9 is a single or double bond; and Y is an alkyl, heteroalkyl, cycloalkyl, aryl, or heteroaryl; or isomers, pharmaceutically acceptable salts, esters or prodrugs thereof.
In a further aspect the present invention provides: (ϋ) A compound according to (i), having the formula:
Figure imgf000004_0001
(I) wherein:
R »2 i •s selected from optionally-substituted aralkyl, optionally-substituted cycloalkyl, optionally-substituted heterocyclyl, optionally-substituted aryl, and Cι_ 4alkyl optionally substituted with one of hydroxy, O(Cι-4alkyl) or S(O) (Cι-4alkyl); A is absent or -O-;
Y is phenyl optionally substituted with one to two groups selected from halo, hydroxy, amino, alkyl or heteroalkyl; or isomers, pharmaceutically acceptable salts, esters or prodrugs thereof; or
(iii) A compound according to (ii), wherein R is selected from cyclopentyl, cyclohexyl, tetrahydropyranyl, piperidinyl, thianonyl, tetrahydro-l,l-dioxide-2-H- thiopyranyl, phenyl, and benzyl, wherein each of said R groups is optionally substituted with one of hydroxy, halogen, O(Cι-4alkyl), or S(O) (Cι-4alkyl); or R .2 is selected from Cι-4alkyl optionally substituted with one of hydroxy, O(Cι-4alkyl) or S(O)2(C1-4alkyl); or
(iv) A compound according to (ii) having the formula,
Figure imgf000004_0002
wherein R is as defined in (ii); or
(v) A compound according to (iv), wherein R is selected from cyclopentyl, cyclohexyl, tetrahydropyranyl, piperidinyl, thianonyl, tetrahydro-l,l-dioxide-2-H- thiopyranyl, phenyl, and benzyl, wherein each of said R groups is optionally- substituted with one of hydroxy, halogen, O(CH3), or S(O)2(CH3); or R2 is selected from Cι-4alkyl optionally substituted with one of hydroxy, O(CH3) or S(O)2(CH3); or
(vi) A compound according to (i), wherein Z is -N-; or
(vii) A compound according to (i) or (vi), wherein Z1 is -C- and the bond between Z1 and C5 is a double bond; or
(viii) A compound according to any one of (i), (vi) or (vii), wherein A is absent or -O-; or
(ix) A compound according to any one of (i), (vi)-(viii), wherein R1 is hydrogen; or
(x) A compound according to any one of (i), (vi)-(ix), wherein R is selected from cyclopentyl, cyclohexyl, tetrahydropyranyl, piperidinyl, thianonyl, tetrahydro- l,l-dioxide-2-H-thiopyranyl, phenyl, and benzyl, wherein each of said R2 groups is optionally-substituted with one of hydroxy, halogen, O(Cι.4alkyl), or S(O)2(Cι.- 4alkyl); or R2 is selected from Cι-4alkyl optionally substituted with one of hydroxy, O(Cι-4alkyl) or S(O)2(Cι-4alkyl); or
(xi) A compound according to any one of (i), (vi)-(x), wherein Y is phenyl optionally substituted with halo, hydroxy, amino, alkyl or heteroaryl; or
(xii) A compound having the formula la,
Figure imgf000005_0001
la wherein Y is aryl; Z is N or CH;
A is absent or O;
R1 is hydrogen;
R is alkyl, hydroxyalkyl, optionally-substituted cycloalkyl, optionally-substituted heteocyclyl, optionally-substituted aryl, or optionally-substituted aralkyl; and the bond between C8 and C9 is a single or double bond; or
(xiii) The compound according to (xii), wherein Z is N, A is -O- and the bond between C8 and C9 is a double bond; or
(xiv) A compound according to (xiii) wherein:
R is 4-tetrahydropyranyl and Y is 4-fluorophenyl; or
R2 is 4-fluorophenyl and Y is 4-fluorophenyl; or
(xv) A compound according to (xii), wherein Z is N, A is absent, and the bond between C8 and C9 is a double bond; or
(xvi) A compound according to (xv), wherein:
R2 is 4-hydroxycyclohexyl and Y is 2-chlorophenyl; R2 is 4-tetrahydropyranyl and Y is 2-chlorophenyl;
R2 is 4-(N-methyl-sulfonylpiperdinyl) and Y is 2-chlorophenyl;
R2 is cyclopentyl and Y is 2-chlorophenyl;
R2 is 4-(N-methyl-sulfonylpiperdinyl) and Y is 2-chlorophenyl;
R2 is 4-tetrahydro,l,l-dioxide-2-H-thiopyranyl and Y is 2-chlorophenyl; R2 is isopropyl and Y is 2-chlorophenyl; or
R2 is 4-fluorbenzyl and Y is 2-chlorophenyl; or
( vii) A compound according to (i), having the formula
Figure imgf000006_0001
(xviii) A compound according to (xvii), wherein Z is N, A is absent, R1 is hydrogen, Y is 2-chlorophenyl, and R is 4-hydroxycyclohexyl; or
(xix) A compound according to (i), having the formula 1(c):
Figure imgf000007_0001
(xx) A compound according to (xix), wherein Z is N, A is absent, R1 is hydrogen, Y is 2-chlorophenyl, and R is 4-hydroxycyclohexyl.
The compounds of formula I and their aforementioned salts are inhibitors of protein kinases and exhibit effective activity against p38 in vivo. Therefore, the compounds can be used for the treatment of diseases mediated by the pro- inflammatory cytokines such as TNF and IL-1. Thus, in another aspect, the present invention relates to methods for the treatment of p38 mediated diseases or conditions in which a therapeutically effective amount of a compound of formula I is administered to a patient in need of such treatment.
In yet another aspect, the present invention relates to methods for preparing the compounds described above.
In yet still another aspect, the present invention relates to methods for preparing medicaments useful for the treatment of the p38 mediated diseases and conditions.
As used herein, the term "alkyl" means a linear saturated monovalent hydrocarbon radical or a branched saturated monovalent hydrocarbon radical of one to six carbon atoms, e.g., methyl, ethyl, n-propyl, 2-propyl, tert-butyl, pentyl, and the like. The term "aryl" refers to a monovalent monocyclic or bicyclic aromatic hydrocarbon radical preferably phenyl which is optionally substituted independently with one or more substituents. When an aryl group is substituted with, preferably one, two or three, substituents, the substituents are preferably selected from the group consisting of alkyl, haloalkyl, halo, hydroxy, nitro, cyano, amino, haloalkoxy, heteroalkyl, methylenedioxy, ethylenedioxy, Y-aryl, Y- heteroaryl, Y-cycloalkyl, Y-heterocyclyl, Y-ORp -Y-NRpRq, -Y-C(O)-Rp, -YS(O)0-2RP. -Y-N-S(O)2Rp, -Y-S(O)2NRpRq, -Y-N-C(O)NRpRq, where Y is absent or a Cι-C3 alkylene group, and Rp and Rq are each independently from each other selected from hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, aryl, heteroaryl, cycloalkyl, and heterocyclyl. More specifically the term aryl includes, but is not limited to, phenyl, chlorophenyl, methoxyphenyl, 1-naphthyl, 2-naphthyl, and the derivatives thereof.
"Aralkyl" means a radical -RxRy where Rx is an alkylene group and R is an aryl group as defined above, e.g. benzyl, phenylethylene, and the like.
The term "cycloalkyl" as used herein refers to a saturated monovalent cyclic hydrocarbon radical of three to seven ring carbons, e.g., cyclopentyl, cyclobutyl, cyclohexyl, and the like. The saturated monovalent cyclic hydrocarbon radical as defined above, may be optionally substituted with one, two or three substituents which are not hydrogen. Preferably, the substituents are selected from the group consisting of alkyl, hydroxy, alkoxy, amino, monosubstituted amino, disubstituted amino, haloalkyl, halo, cyanoalkyl, oxo (i.e., carbonyl oxygen), heteroalkyl, heterocyclyl, hydroxyalkyl, and -(X)n-C(O)R' (where, X is O or NR", n is 0 or 1, R" is hydrogen, alkyl, haloalkyl, amino, monosubstituted amino, disubstituted amino, hydroxy, alkoxy, alkyl or optionally substituted phenyl, and R' is H or alkyl), and -S(O)nR' (wherein n is 0 to 2). More specifically, the term substituted cycloalkyl includes, for example, substituted cyclopentyl, substituted cyclohexyl, and the like.
The term "halo," "halide" or "halogen," when referring to a substituent means fluoro, chloro, bromo, or iodo, preferably chloro.
The term "haloalkyl" means alkyl substituted with one or more same or different halo atoms, e.g., -CH2CI, -CF3, -CH2CF3, -CH2CCI3, and the like, and further includes those alkyl groups such as perfluoroalkyl in which all alkyl hydrogen atoms are replaced by fluorine atoms.
The term "heteroalkyl" as used herein means an alkyl radical defined above, wherein one, two or three hydrogen atoms have been replaced with a substituent independently selected from the group consisting of -ORa, -NRbRc, and S(O)nRd (where n is an integer from 0 to 2), with the understanding that the point of attachment of the heteroradical is through a carbon atom, wherein Ra is hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylalkyl; or Rb and Rc are independently of each other hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylakyl, or Rb and Rc together with the nitrogen atom to which they are attached form heterocyclo or heteroaryl; and when n is 0, Rd is hydrogen, alkyl, cycloalkyl, or cycloalkylakyl, and when n is 1 or 2, Rd is alkyl, cycloalkyl, cycloalkylalkyl, amino, acylamino, monoalkylamino, or dialkylamino. Representative examples include, but are not limited to, 2- hydroxyethyl, 3-hydroxypropyl, 2-hydroxymethylethyl, 2,3-dihydroxypropyl, 1-hydroxy-methylethyl, 3-hydroxybutyl, 2,3-dihydroxybutyl, 2-hydroxy-l- methylpropyl, 2-aminoethyl, 3-aminopropyl, 2-methylsulfonylethyl, aminosulfonylmethyl, aminosulfonylethyl, methylaminosulfonylmethyl, methylaminosulfonylethyl, methylaminosulfonylpropyl, and the like. When Ra is hydrogen, the radical -ORa is also referred to as "hydroxyalkyl" and includes, but is not limited to, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxymethylethyl,
2,3-dihydroxypropyl, 1-hydroxymethylethyl, 3-hydroxybutyl, 2,3-dihydroxybutyl, and 2-hydroxy-l-methylpropyl.
"Heteroaryl" means a monvalent monocyclic or bicyclic radical of 5 to 12 ring atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, with the understanding that when the heteroaryl is a bicyclic system in which one of the rings is carbocyclic and/or non-aromatic, the attachment point of the heteroaryl radical will be on a heteroaryl ring. The heteroaryl ring is optionally substituted with one or more substituents, preferably one or two substituents, independently from each other selected from alkyl, haloalkyl, halo, nitro, cyano, amino, methylenedioxy, Y-aryl, Y-heteroaryl, Y-cycloalkyl, -Y-heterocyclyl, -Y-OR', -YNR'R", -Y-C(O)R\ -Y-O-C(O)-R', -Y-S(O)0-2-R\ -Y-N-SO2-R', -Y-SO2- NR'R", and -Y-N-C(O)-NR'R", where Y is absent or a Cι-C3 alkylene group and R' and R" are each independently from each other hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, aryl, heteroaryl, cycloalkyl, or heterocyclyl. More specifically, the term heteroaryl includes, but is not limited to, pyridyl, furanyl, thienyl, thiazolyl, isothiazolyl, triazolyl, imidazolyl, isoxazolyl, pyrrolyl, pyrazolyl, pyrimidinyl, benzofuranyl, tetrahydrobenzofuranyl, isobenzofuranyl, benzo- thiazolyl, benzoiosthiazolyl, benzotriazolyl, indolyl, isoindolyl, benzoxazolyl, quinolyl, tetrahydroquinolnyl, isoquinolyl, benzimidazolyl, benzisoxazolyl or benzothienyl, imidazo[l,2-a]-pryidinyl, imidazo[2,l-b]thiazolyl, and derivatives thereof. "Monosubstituted amino" means a radical -NHRe where Re is alkyl, heteroalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heterocyclyl, or heterocyclylalkyl, e.g., methylamino, ethylamino, phenylamine, benzylamine, and the like. Similarly, the term "disubstituted amino" refers to a radical -NRgRh wherein Rs and Rhare, independently of each other, alkyl, heteroalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heterocyclyl, or heterocyclylalkyl, or Rg and Rh together with the nitrogen atom to which they are attached form a heterocyclyl ring. Representative examples include, but are not limited to, dimethylamino, methylethylamino, di(l-methyl-ethyl)amino, piperazinyl, and the like.
"Heterocyclyl" means a saturated cyclic radical in which one or two ring atoms are heteroatoms selected from N, O, or S(O)n (where n is an integer from 0 to 2), the remaining ring atoms being C, where one or two C atoms may optionally contain a carbonyl oxygen group, e.g., one or two atoms in the ring may be a moiety of the formula -C(=O)-. The heterocyclyl ring may be optionally substituted independently with one, two, or three substituents selected from alkyl, hydroxy, hydroxyalkyl, alkoxy, heteroalkyl, haloalkyl, and -(X)n-C(O)R (where, X is O or NR', n is 0 or 1, R is hydrogen, alkyl, haloalkyl, amino, monosubstituted amino, disubstituted amino, hydroxy, alkoxy, or optionally-substituted phenyl, and R' is H or alkyl), Y-aryl, Y-heteroaryl, Y-cycloalkyl, Y-heterocyclyl, Y-ORp, -Y- NRpRq, -Y-C(O)-Rp, -YS(O)o_2Rp. -Y-N-S(O)2Rp, -Y-S(O)2NRpRq, -Y-N- C(O)NRpRq, where Y is absent or a Cι-C3 alkylene group, and Rp and Rq are each independently from each other selected from hydrogen, alkyl, haloalkyl, hydroxy, alkoxy, aryl, heteroaryl, cycloalkyl, and heterocyclyl. More specifically the term heterocyclyl includes, but is not limited to, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, and the derivatives thereof. The term "acyl" refers to the group -C(O)Rrwhere Rr is alkyl, haloalkyl, heteroalkyl, aryl, heteroaryl, aralkyl or heteroaralkyl.
"Alkoxy", "aryloxy", " aralkyloxy", or "heteroaralkyloxy" means a radical - OR where R is an alkyl, aryl, aralkyl, or heteroaralkyl, respectively, as defined above, e.g., methoxy, phenoxy, pyridin-2-ylmethyloxy, benzyloxy, and the like. When a bond appears in a formula herein as a double bond wherein one of
the two bonds appears as a dotted line, as in
Figure imgf000011_0001
, it should be understood that unless otherwise specifically stated, this notation means the bond optionally may be a single bond or a double bond, with appropriate selections being made for adjacent atoms. Thus, when it is stated "the dotted line is a bond," this means a double bond is present; and when it is stated "the dotted line is not a bond," this means a single bond is present.
"Leaving group" has the meaning conventionally associated with it in synthetic organic chemistry, i.e., an atom or a group capable of being displaced by a nucleophile and includes halo (such as chloro, bromo, and iodo), alkanesulfonyloxy, arenesulfonyloxy, alkylcarbonyloxy (e.g., acetoxy), arylcarbonyloxy, mesyloxy, tosyloxy, trifluoromethanesulfonyloxy, aryloxy (e.g., 2,4-dinitrophenoxy), methoxy, N-O-dimethylhydroxylamino, and the like.
"Pharmaceutically acceptable excipient" means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. A "pharmaceutically acceptable excipient" as used in the specification and claims includes both one and more than one such excipient.
"Pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2- ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4- chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-lcarboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-l-carboxylic acid), 3- phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, trimethamine, N-methylglucamine, and the like.
The terms "pro-drug" and "prodrug" are used interchangeably herein and refer to any compound which releases an active parent drug according to Formula I in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of Formula I are prepared by modifying one or more functional group(s) present in the compound of Formula I in such a way that the modification(s) may be cleaved in vivo to release the parent compound. Prodrugs include compounds of Formula I wherein a hydroxy, amino, or sulfhydryl group in a compound of Formula I is bonded to any group that may be cleaved in vivo to regenerate the free hydroxyl, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups in compounds of Formula I, and the like.
"Protecting group" refers to a grouping of atoms that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in T.W. Green and P.G. Futs, Protective Groups in Organic Chemistry, (Wiley, 2nd ed. 1991) and Harrison and Harrison et al., Compendium of Synthetic Organic Methods, Nols. 1-8 (John Wiley and Sons, 1971-1996). Representative amino protecting groups include, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (CBZ), tert-butoxycarbonyl (Boc), trimethyl silyl (TMS), 2-trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (FMOC), nitro- veratryloxycarbonyl (NVOC), and the like. Representative hydroxy protecting groups include those where the hydroxy group is either acylated or alkylated such as benzyl, and trityl ethers as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers and allyl ethers.
"Treating" or "treatment" of a disease includes: (1) preventing the disease, i.e., causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease; (2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or (3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms. "A therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
In one embodiment, the present invention provides compounds represented by the formula:
Figure imgf000013_0001
(I) wherein Z, Z1, R1, R2, A, Y, and the bonds between C5 and Z1 and C8 and C9 are as defined above.
Preferred compounds of formula I includee those wherein A is absent or - O-, both Z and Z1 are N, Y is an aryl, R1 is hydrogen, and R2 is as defined above for compounds of formula (I). More preferred compounds are compounds of formula I, wherein Z is N, Z1 is C such that the bond between C5 and Z1 is a double bond, A is absent or -O, Y is aryl (more preferably optionally-substituted phenyl), R is hydrogen, and R is as defined above for compounds of formula I. Still more preferred compounds are compounds of formula 1(a):
Figure imgf000014_0001
1(a) wherein Z is N, A or absent or -O-, Y is optionally-substituted phenyl, R1 is hydrogen, and R2 is as defined above.
Most preferred compounds are those of formula 1(a) wherein Z is N, A is absent, Y is a phenyl substituted with a halo, hydroxy, amino, alkyl or heteroalkyl, R1 is hydrogen, and R2is alkyl, heteroalkyl, optionally-substituted cycloalkyl, optionally-substituted heterocycyl or substituted phenyl or benzyl.
Particularly preferred compounds are compounds of formula 1(a) wherein A is absent, Y is phenyl substituted with a halo, the dotted line is a double bond, R1 is hydrogen, and R is alkyl (more preferably lower alkyl optionally substituted with hydroxy, methoxy or methylsulfonyl), heteroalkyl, optionally-substituted cycloalkyl (more preferably cyclopentyl or cyclohexyl optionally substituted with methoxy), optionally-substituted heterocycyl (more preferably optionally- substituted piperidinyl), or substituted phenyl or benzyl (more preferably phenyl or benzyl substituted with a halo). Table I below lists some of the representative compounds of formula 1(a).
Other representative compounds of the invention are compounds of formula
Kb).
Figure imgf000014_0002
1(b) wherein R , Z, R , A and Y are as defined above for compounds of formula (I) and 1(a). Still other representative compounds of the invention are compounds of formula 1(c)
Figure imgf000015_0001
wherein Z, R1, R2, A and Y are as defined above for compounds of formula (I) and 1(a).
A preferred compound (12) of formula 1(c) is wherein Z is N, A is absent, R is hydrogen, Y is 2-chlorophenyl, and R is 4-hydroxycyclohexyl. Mass spectra of MH+ 399.
Table 1
Representative compounds of formula 1(a) are compounds wherein the dotted line is a bond, Z is N, R1 is hydrogen, and the values of R2, A, and Y are as set forth below:
Figure imgf000015_0002
1(a)
Table 1
Figure imgf000016_0001
A preferred compound (13) of formula 1(a) is a compound wherein Z is N, the dotted line is not a bond, R1 is hydrogen, R2 is 4-hydroxycylcohexyl, and Y is 2-chlorophenyl. MH+ 396, M.P. 169.3°C to 175.8°C.
Particularly preferred compounds of formula 1(a) are compounds (3) and (7) of Table 1, above.
The compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms and are intended to be encompassed within the scope of the invention. Furthermore, as stated above, the present invention also includes all pharmaceutically acceptable salts of the compounds along with prodrug forms of the compounds and all stereoisomers whether in a pure chiral form or a racemic mixture of other forms of mixture.
The compounds of formula I are capable of further forming pharmaceutically acceptable acid addition salts. All of these forms are also contemplated within the scope of the claimed invention. Pharmaceutically acceptable acid addition salts of the compounds of formula I include salts derived from inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, phosphorus, and the like, as well as the salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydro- genphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, pthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartarate, methane- sulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge et al., "Pharmaceutical Salts," J. of Pharmaceutical Science, 1977, 66, 1-19). The acid addition salts of the basic compounds can be prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form can be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The free base forms may differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for the purposes of the present invention. Pharmaceutically acceptable base addition salts can be formed with metal ions or amines, such as alkali and alkaline earth metal ions or organic amines. Examples of metal ions which are used as cations include sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N, N'- dibenzylethylenediamine, chlororocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., supra).
The basic addition salts of acidic compounds can be prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form can be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms may differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for the purposes of the present invention.
The compounds of the present invention can be prepared by a variety of methods, using procedures well-known to those of skill in the art. The following schemes illustrate the processes of making the compounds of the invention with the abbreviations used herein have the following meaning:
MCPBA: m-chloroperbenzoic acid.
NMP: l-methyl-2-pyrrolidinone. THF: tetrahydrofuran.
TLC: thin layer chromatography.
EtOAc: ethyl acetate.
LAH: lithium aluminum hydride.
DMF: dimethylformamide DMPU: l,3-dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidinone
Scheme 1 describes a general method of synthesizing compounds of formula 1(a) (1) (compounds of formula 1(a) wherein the dotted line is not a bond) starting with a protected thiopyridine-5-carboxylate 1, wherein Rp and Rpa are protecting groups such as lower alkyl and benzyl; and RL is a leaving group such as a halo. The protecting and leaving groups are as defined on page 6, lines 30 through page 7, line 9 and page 5, lines 22-26, respectively. The general method of preparing compound 5 from carboxlyate 1 in the Scheme is described in WO 0129042 and WO 0129041.
Compound 1 is treated with triethylamine and aqueous ammonium to afford compound 2. Compound 2 is reduced with lithium aluminum hydride or other reducing agents well known in the art to yield compound 3. Compound 3 is oxidized to aldehyde 4 by treating it with activated manganese oxide powder or by other oxidizing methods known in the art. Compound 4_is reacted with an ester of general formula -A-Y-C(O)ORz, wherein A and Y are as defined above and Rz is lower alkyl, aryl or cycloalkyl, to afford pyrimidinone 5.
Compound 5_is reacted with N-(2-hydroxyethyl)-phthalimide to obtain phthalimide 6. The phthalimide 6 is stirred with hydrazine mononhydrate and compound 7_isolated in a pure form. Compound 7 is cyclized into tricyclic sulfide 8 by reacting it with trimethylaluminum.
Tricyclic sulfide 8 may be directly reacted with an amine of the general formula -NH R R to afford a compound of general formula 1(a)(1).
Scheme 1
Figure imgf000020_0001
1(a)(1)
Scheme 2 describes a general method of preparing a compound of formula 1(a)(2) (compounds of formula 1(a) wherein the dotted line is a bond), by starting with the aldehyde 4 from Scheme 1 above and heating it with a cyanide of general formula CN-CH2-A-Y, wherein A and Y are as defined above, and potassium carbonate in DPMU to obtain aminopyridopyrimidine 9. Compound 9 is treated with triethylamine and 1,2-dichloroethyl ethyl ether to afford sulfide of formula 10.
Compound 10_is then oxidized to the corresponding sulfoxide 11 by the method described in Scheme 1. The sulfoxide 11 is then reacted with the amine of formula -NH^R2 to afford a compound of general formula 1(a). Alternatively, sulfide 10 can be reacted directly with -NH^R2 to afford a compound of general formula 1(a)(2). Scheme 2
Figure imgf000021_0001
Figure imgf000021_0002
10 11
Figure imgf000021_0003
a 2)
Scheme 3 describes a general method of preparing compound of formula 1(c) starting with compound 12. Compound 12 is prepared according to the method described in WO 0129042 and WO 0129041.
Scheme 3
Figure imgf000022_0001
l(c)
Compound Y2 is treated with triphenylphosphine, diethylazodicarboxylate and N- (2-hydroxyethyl)-phthalimide to obtain compound 13. Compound 13 is then reacted with hydrazine hydrate to obtain compound 14, which is then reacted with trimethylaluminum solution to obtain compound 15. Compound 15 is reacted with an amine of formula -H2NR R to obtain a compound of formula 1(c). Alternatively, compound 15 can be oxidized with 3-chloroperbenzoic acid to obtain the corresponding sulfoxide (not shown) which is then reacted with amine -NR!R2 to obtain the desired compound of formula I (c).
These processes for the preparation of the compounds of the present invention are also an object of this invention, including the following processes:
(i) A process of making a compound according to Claim 1, comprising: reacting a compound of formula A with a cyanide of formula CN-CH2-A-Y wherein A, Z and Y are as defined in Claim 1, and Rp is selected from lower alkyl and benzyl, to afford a compound of formula B;
Figure imgf000022_0002
b) treating compound B with a reagent selected from triethylamine, trialkylamine base, l,4-diazabicyclo[2.2.2]octane, or disopropylethylamine, and 1,2-dichloro- ethylether to obtain compound C;
Figure imgf000023_0001
c) oxidizing compound C with a reagent selected from 3-chloroperbenzoic acid, hydrogen peroxide/formic acid, hydrogen peroxide/methyltrioxorhenium VII, or OXONE, to obtain compound D; and
Figure imgf000023_0002
D
1 1 d) contacting compound D with an amine of formula -H N-R R wherein R and R2 are as defined in claim 1 for a sufficient period of time to obtain the compound according to Claim 1.
(ii) A process of preparing a compound according to Claim 1 comprising: a) reacting a compound of formula E wherein Z, A and Y are as defined in Claim 1 and Rp is lower alkyl or benzyl, with a reagent selected from triphenylphosphine, diethylazodicarboxylate, and N-(2-hydroxyethyl)-phthalimide to obtain compound F;
Figure imgf000023_0003
b) reacting compound F with a hydrazine to obtain compound G;
Figure imgf000024_0001
G c) reacting compound G with trimethylaluminum to obtain compound H;
Figure imgf000024_0002
H d) optionally oxidizing compound H with a reagent selected from 3- chloroperbenzoic acid, hydrogen peroxide/formic acid, hydrogen peroxide/ methyltrioxorhenium VII, or OXONE, to obtain the corresponding sulfoxide and contacting the sulfoxide with an amine of formula -H2N-R'R2 wherein R1 and R2 are as defined in claim 1 for a sufficient period of time to obtain the compound according to Claim 1.
The compounds of formula I and the pharmaceutically acceptable salts of basic compounds of formula I with acids can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered enterally, e.g. orally in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, nasally, e.g. in the form of nasal sprays, or rectally, e.g. in the form of suppositories. However, they may also be administered parenterally, e.g. in the form of injection solutions. The compounds of formula I and their aforementioned pharmaceutically acceptable salts can be processed with pharmaceutically inert, organic or inorganic carriers for the production of pharmaceutical preparations. Lactose, com starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active ingredient no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
The pharmaceutical preparations can also contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain therapeutically valuable substances other than the compounds of formula I and their aforementioned pharmaceutically acceptable salts.
Medicaments which contain a compound of formula I or a pharmaceutically acceptable salt of a basic compound of formula I with an acid in association with a compatible pharmaceutical carrier material are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more of these compounds or salts and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with a compatible pharmaceutical carrier.
As mentioned earlier, the compounds of formula I and their aforementioned pharmaceutically acceptable salts can be used in accordance with the invention as therapeutically active substances, especially as antiinflammatory agents or for the prevention of graft rejection following transplant surgery. The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of administration to adults a convenient daily dosage should be about 0.1 mg/kg to about 100 mg/kg, preferably about 0.5 mg/kg to about 5 mg/kg. The daily dosage may be administered as a single dose or in divided doses and, in addition, the upper dosage limit referred to earlier may be exceeded when this is found to be indicated.
Finally, the use of compounds of formula I and their aforementioned pharmaceutically acceptable salts for the production of medicaments, especially in the treatment or prophylaxis of inflammatory, immunological, oncological, bronchopulmonary, dermatological and cardiovascular disorders, in the treatment of asthma, central nervous system disorders or diabetic complications or for the prevention of graft rejection following transplant surgery, is also an object of the invention.
Compounds of Formula I would be useful for, but not limited to, the treatment of any disorder or disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated TNF or p38 kinase production by such mammal. Accordingly, the present invention provides a method of treating a cytokine-mediated disease which comprises administering an effective cytokine- interfering amount of a compound of Formula I, or a pharmaceutically acceptable salt or tautomer thereof.
Compounds of Formula I would be useful for, but not limited to, the treatment of inflammation in a subject, and for use as antipyretics for the treatment of fever. Compounds of the invention would be useful to treat arthritis, including but not limited to, rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, and other arthritic conditions. Such compounds would be useful for the treatment of pulmonary disorders or lung inflammation, including adult respiratory distress syndrome, pulmonary sarcoidosis, asthma, silicosis, and chronic pulmonary inflammatory disease. The compounds are also useful for the treatment of viral and bacterial infections, including sepsis, septic shock, gram negative sepsis, malaria, meningitis, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), pneumonia, and herpes virus. The compounds are also useful for the treatment of bone resorption diseases, such as osteoporosis, endotoxic shock, toxic shock syndrome, reperfusion injury, autoimmune disease including graft vs. host reaction and allograft rejections, cardiovascular diseases including atherosclerosis, thrombosis, congestive heart failure, and cardiac reperfusion injury, renal reperfusion injury, liver disease and nephritis, and myalgias due to infection. The compounds are also useful for the treatment of influenza, multiple sclerosis, cancer, diabetes, systemic lupus erthrematosis (SLE), skin-related conditions such as psoriasis, eczema, burns, dermatitis, keloid formation, and scar tissue formation. Compounds of the invention also would be useful to treat gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis. The compounds would also be useful in the treatment of ophthalmic diseases, such as retinitis, retinopathies, uveitis, ocular photophobia, and of acute injury to the eye tissue. Compounds of the invention also would be useful for treatment of angiogenesis, including neoplasia; metastasis; ophthalmological conditions such as corneal graft rejection, ocular neovascularization, retinal neovascularization including neovascularization following injury or infection, diabetic retinopathy, retrolental fibroplasia and neovascular glaucoma; ulcerative diseases such as gastric ulcer; pathological, but non-malignant, conditions such as hemangiomas, including infantile hemangiomas, angiofibroma of the nasopharynx and avascular necrosis of bone; diabetic nephropathy and cardiomyopathy; and disorders of the female reproductive system such as endometriosis. The compounds of the invention may also be useful for preventing the production of cyclo-oxygenase-2.
Besides being useful for human treatment, these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats. The present compounds may also be used in co-therapies, partially or completely, in place of other conventional antiinflammatories, such as together with steroids, cyclooxygenase-2 inhibitors, NSAIDs, DMARDS, immunosuppressive agents, 5-lipoxygenase inhibitors, LTB4 antagonists and LTA4 hydrolase inhibitors. As used herein, the term "TNF mediated disorder" refers to any and all disorders and disease states in which TNF plays a role, either by control of TNF itself, or by TNF causing another monokine to be released, such as but not limited to IL-1, IL-6 or IL-8. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore be considered a disorder mediated by TNF.
As used herein, the term "p38 mediated disorder" refers to any and all disorders and disease states in which p38 plays a role, either by control of p38 itself, or by p38 causing another factor to be released, such as but not limited to IL- 1, IL-6 or IL-8. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to p38, would therefore be considered a disorder mediated by p38.
As TNF-β has close structural homology with TNF-α (also known as cachectin), and since each induces similar biologic responses and binds to the same cellular receptor, the synthesis of both TNF-α and TNF-β are inhibited by the compounds of the present invention and thus are herein referred to collectively as "TNF" unless specifically delineated otherwise.
EXAMPLES
Example 1 (Compound #12)
Figure imgf000028_0001
This example illustrates preparation of compound of formula 1(c)
Figure imgf000028_0002
Ste l
To a suspension of 3.0 g (7.84 mmol) of pyrimidinone A, 4.12 g (15.7 mmol) of triphenylphosphine and 4.12 g (15.7 mmol) of N-(2-hydroxyethyl)- phthalimide in 45 mL of 1,4-dioxane at 5°C was added dropwise a solution of 2.73 g (2.5 mL, 15.7 mmol) of diethylazodicarboxylate in 10 mL of 1,4-dioxane over a period of 20 min. through an additional funnel. The suspension was stirred at 5°C for 1 hour and then at room temperature overnight at which point the suspension turned into a yellow solution. The solution was concentrated in vacuo and the residue was purified by column chromatography with silica eluting with 7.5% ethyl acetate in dichloromethane affording 3.92 g of the phthalimide i (90% yield).
Step 2
Figure imgf000029_0001
A mixture of 1.5 g (2.7 mmol) of the phthalimide 1 from Step 1 was stirred with 2.0 mL of hydrazine hydrate in 100 mL of methanol overnight at room temperature. The solution was concentrated in vacuo and the residue was partitioned between chloroform and water. The chloroform solution was washed with brine, dried (MgSO4) and concentrated. The product was purified by column chromatography with silica eluting with 10% methanol in dichloromethane affording 1.0 g of the intermediate 2 (87% yield). Step 3
Figure imgf000029_0002
To a solution of 1.56 g (3.7 mmol) of compound 2 in 30 mL of toluene was added dropwise 2.3 mL of trimethylaluminum solution (2M in toluene, 4.6 mmol). The reaction mixture was heated to reflux for one hour until completion. The toluene was removed in vacuo and the residue was quenched with 100 mL of saturated aqueous NHtCl and 100 g of ice. 200 mL of ethyl acetate was added and the mixture was filtered. The solid collected was again mixed with 200 mL of ethyl acetate and 200 mL of water. This was stirred for 15 minutes and filtered. This operation was repeated one more time. All three filtrates were combined and transferred to a separatory funnel and the layers were separated. The aqueous layer was extracted once more with ethyl acetate. The combined ethyl acetate solution (about 800 mL) was washed with brine and dried (MgSO4) and removed in vacuo affording 1.4 g of the tricyclic compound 5_(light yellow solid, 94% yield). Step 4
Figure imgf000030_0001
Compound 12
A solution of 0.171 g (0.42 mmol) of tricyclic-sulfide 3_m 20 mL of dichloromethane was cooled to 5°C. 0.094 g (0.42 mmol) of 3-chloroperbenzoic acid (77% max.) was added. The mixture was stirred for 30 minutes until completion and the solution was poured in saturated aqueous Na2SO3, extracted with dichloromethane (2 X 75 mL). The dichloromethane was then washed with cold saturated aqueous NaHCO , brine and dried (MgSO4). The solvent was removed in vacuo recovering 0.17 g of the sulfoxide (96% yield). This sulfoxide was mixed with 0.21 g (1.8 mmol) of trαn-s^-aminocyclohexanol and 1 mL of NMP was heated in a 120°C oil bath for 45 minutes until reaction was completed. The mixture was diluted with water and extracted with ethyl acetate (3 X 30 mL). The combined ethyl acetate solution was then washed with water (3 X 30), brine, and dried (MgSO4). The solvent was removed in vacuo and residue recovered was purified by column chromatography with silica eluting with MeOH/CH2Cl2/Et3N (1/9/0.4), affording 19 mg of compound 13. (mass spec. M+l = 399) Example 2 (Compound 13) This example illustrates the preparation of compound of formula I (a) following the procedure described in Scheme 1. Step l
Figure imgf000031_0001
To a suspension of 3.0 g (9.88 mmol) of pyridone B, 5.18 g (19.8 mmol ) of triphenylphosphine and 3.78g (19.8 mmol) of N-(2-hydroxyethyl)-phthalimide in 45 ml of 1,4-dioxane at 5°C was added dropwise a solution of 2.73 g (2.5 ml, 15.7 mmol) of diethylazodicarboxylate in 10 ml of 1,4-dioxane over a period of 20 min. through an additional funnel. The suspension was then stirred at 5°C for 1 hour and then at room temperature overnight. The suspension was filtered and the solid was washed with methanol, then ether. The white solid, 2.17 g was the desired material. The filtrate was concentrated and purified by column chromatography with silica eluting with 5% ethyl acetate in hexanes affording another 1.2 g of the desired product. Total yield of 4 was 71%. Step 2
Figure imgf000031_0002
To a suspension of 1.2 g (2.5 mmol) of phthalimide 4 in 100 ml of methanol was added 6 ml of hydrazine monohydrate. This was stirred at room temperature overnight upon which the suspension turned into a clear yellow solution. The mixture was concentrated and residue was diluted with water and extracted with chloroform. The organic solution was washed with brine and dried (MgSO4), and the residue was purified by column chromatography with silica eluting with 10% methanol in dichloromethane affording 0.48 g of the aminoethyl- pyridone 5 (55% yield). Step 3
Figure imgf000032_0001
To a solution of 0.48 g (1.4 mmol) of compound 5 in 10 mL of toluene was added dropwise 0.87 mL of trimethylaluminum solution (2M in toluene, 1.76 mmol). The reaction mixture was heated to reflux for two hours until completion. The toluene was removed in vacuo and the residue was quenched with 50 mL of saturated aqueous NH-tCl and was extracted with ethyl acetate (3 X 75 mL). The combined organic solution was washed with brine and dried (MgSO4) and removed in vacuo affording 0.36 g of the tricyclic compound 6 (80% yield). Step 4
Figure imgf000032_0002
6 Compound 13
A mixture of 0.1 g (0.3 mmol) of compound 6 and 0.325 g (1 mmol) of trø7z.s-4-aminocyclohexanol in 0.5 mL of NMP was heated in a 200°C sand-bath (heating mantle) for 14 hours. After cooling the mixture was diluted with water and extracted with ethyl acetate (3 X 50 mL). The combined organic solution was washed with water (3 X 50 mL), brine and dried (MgSO4). The solvent was removed in vacuo and the product was purified by column chromatography with silica eluting with a gradient of 5% to 20% methanol in dichloromethane affording 0.102 g of compound 13. (mass spec. M+l = 396, MP = 169.3 - 175.8°C).
Example 3j, (Compound 1)
Figure imgf000033_0001
Step l 4-amino-2-benzylsulfanyl-pyrimidine-5-carboxylate
Figure imgf000033_0002
1 8
A mixture of 5g (20.4 mmol) of aldehyde 7, 3.71g (24.4 mmol) of 2-chlorobenzylcyanide and 18g (130 mmol) of potassium carbonate in 50 mL of DMPU was heated in a 110°C oil bath for 3 hours until the reaction was completed. The mixture was poured into 600 ml of water and extracted with 300 mL of ethyl acetate. The organic solvent was washed with water (3 X 250mL), diluted with 200 mL of hexanes, washed with brine, dried (MgSO4), and filtered through a short plug of silica. The solvent was removed in vacuo. Residual solid was stirred in 50 mL of ethyl acetate for 30 minutes. The solid was filtered off and washed with small amount of ethyl acetate, recovering 2.23 g of the aminopyridopyrimidine 8. The filtrate was concentrated and the residue was purified by column chromatography with silica eluting with 50% ethyl acetate in hexanes, isolating an additional 0.62 g of 2-benzylsulfanyl-6-(2-chloro-phenyl)-pyrido[2,3-d]pyrimidin- 7-ylamine 8 (total yield: 37%). Step 2
Figure imgf000034_0001
8
To a mixture of 3 g (7.9 mmol) of amine 8, 4.8 g (6.6 mL, 47.6 mmol) of triethylamine, 5 mL of water and 50 mL of acetonitrile was added a total of 4.0 mL (32 mmol) of 1,2-dichloroethyl ethyl ether over a period of 6 hours (1 equivalent/hour the first two hours and 0.5 equivalent/hour the following four hours), until reaction was completed. The mixture was allowed to stand overnight at room temperature, diluted with water and extracted with ethyl acetate (2 X 100 mL). The organic solution was washed with brine and dried (MgSO4) and removed in vacuo. Purification was done by column chromatography with silica eluting with 30% ethyl acetate in hexanes affording 2 g of the sulfide 9 (63% yield).
Step 3
Figure imgf000034_0002
9 Compound 1
A mixture of 0.056g (0.14 mmol) of compound 9_and 0.053 g (0.46 mmol) of trαn-s-4-aminocyclohexanol in 1 mL of NMP was heated in a 205°C sand-bath (heating mantle) for 14 hours. After cooling the mixture was diluted with water and extracted with ethyl acetate (3 X 50 mL). The combined organic solution was washed with water (3 X 50 mL), brine and dried (MgSO4). The solvent was removed in vacuo affording 0.39 g of the desired compound 1 (Compound 1). (mass spec. M+l = 394, MP = 116 - 119°C). Step 4
Figure imgf000035_0001
10
Optionally, to a cooled solution of 2 g (5 mmol) of the sulfide 9 in 60 mL of dichloromethane at 5°C was added 1.11 g (5 mmol) of 3-chloroperbenzoic acid (77% max.). The reaction was completed in 3 hours and the mixture was poured into saturated aqueous NaHCO3 and extracted with dichloromethane. The organic solution was then washed with 10% aqueous NaHSO3, brine and dried (MgSO4). After removal of solvent in vacuo, 2 g of the sulfoxide 10 was recovered. (96% yield). The corresponding methylsulfoxide (substituting Bn for Me) was prepared in a similar manner. The sulfoxide 10 was then converted into compound #1 as described in Step 4 above.
Example 4 (Compound 3)
Figure imgf000035_0002
Preparation of l-(methylsulfonyl)piperidine-4-amine (15) Step l Benzyl l-benzylpiperidin-4-ylcarbamate
Figure imgf000035_0003
11 12 To a 0 °C solution of 4-amino-l-benzylpiperidine H (41.2 g, 216.5 mmol) and triethylamine (51.3 mL, 369 mmol) in 600 mL of tetrahydrofuran was added benzyl chloroformate (31 mL, 217 mmol) dropwise over a period of 30 to 45 min. at such a rate that the reaction temperature was kept between 5 °C and 10 °C. After the addition was complete, the reaction mixture was allowed to warm to room temperature and stir for 12 hours. The solvent and volatiles were removed under reduced pressure. Water (500 mL) and ethyl acetate (1.2 L) were then added and the reaction was partitioned between the two phases. The organic layer was washed with saturated aqueous sodium bicarbonate solution (2X, 150 mL) and then dried (brine, MgSO4). Evaporation of the solvent yielded a tan liquid which was purified via column chromatography (SiO , EtOAc/Hexane - 30/70 to EtOAc - 100) to provide 27.8 g of the amine 12 as a white solid (mass spec. M+ = 324, MP = 79.1 - 79.6 °C). Step 2 Benzyl piperidin-4-ylcarbamate
Figure imgf000036_0001
12 13
The benzyl amine 12 (27.8 g, 85.7 mmol) was dissolved in 400 mL of methylene chloride at room temperature and 1-chloro-ethylchloroformate (25.4 g, 178 mmol) in 50 mL of methylene chloride was added dropwise via addition funnel. After addition was complete, the reaction mixture was stirred at room temperature for 3 hours. The solvent and volatiles were removed under reduced pressure and methanol (500 mL) was added. The reaction was heated to reflux with stirring for 1 hour and then cooled to room temperature. Removal of the reaction solution via evaporation yielded 26.3 g of the piperidine 13 as an off-white solid (mass spec. M+l = 235, MP = 190.7 - 192.2 °C). Step 3 Benzyl l-(methylsulfonyl)piperidin-4-ylcarbamate
Figure imgf000036_0002
13 14 The protected piperidine 13 (10 g, 42.7 mmol) and triethylamine (12 mL, 86.7 mmol) was dissolved in 500 mL of methylene chloride at room temperature. Methane sulfonylchloride (4.3 mL, 55.5 mmol) in 20 mL of methylene chloride was added dropwise via addition funnel. After addition was complete, the reaction mixture was stirred at room temperature for 3 hours. The solvent and volatiles were removed under reduced pressure. Ethyl acetate (500 mL) and an aqueous solution of hydrochloric acid (0.5M, 350 mL) was added. The reaction was partitioned between the two phases and the aqueous layer was removed. The organic layer was washed again with an aqueous solution of hydrochloric acid (0.5M, 2X, 100 mL) and then with saturated aqueous sodium bicarbonate solution (3X, 100 mL). The reaction solvent was then dried (brine, MgSO4) and evaporated at reduced pressure to provide 9.2 g of the methane sulfonamide 14 (MP = 148.6 - 152.8 °C). Step 4 l-(methylsulfonyl)piperidin-4-amine
Figure imgf000037_0001
14 15
The methane sulfonamide 14 (9.2 g, 29.5 mmol) was dissolved in 200 mL of tetrahydrofuran at room temperature in a 500 mL round-bottomed flask under a nitrogen atmosphere. Palladium on Carbon (10%, 2 - 3 g) was then added and the reaction vessel was flushed with hydrogen gas (3X). A balloon of hydrogen gas was put on the reaction flask and the solution was stirred for 15 hours (more catalyst added and hydrogen balloon filled if necessary). Methylene chloride (100 mL) was added to the reaction and it was filtered through a celite pad. Evaporation of the solvents under reduced pressure provided 4.63 g of the desired amine L5 (mass spec. M+l = 179, MP = 65.3 - 65.7 °C). Step 5
A mixture of 0.6 g (1.43 mmol) of sulfoxide 10 from Example 3 and 0.51 g (2.86 mmol) of the l-(methylsulfonyl)piperidine-4-amine 15 in 1 mL of NMP was heated to 70 to 80°C for 1 hour. This was cooled and diluted with water and extracted with ethyl acetate (2 X 75 mL). [Starting material 15 and product had the same Rf value on TLC (5% MeOH7CH2Cl2 ), mass spec, of reaction product: M+l = 457)]. The organic solution was washed with water (2 X 75 mL), brine and dried (MgSO4) and concentrated. The residue was purified by column chromatography eluting with 30% ethyl acetate in dichloromethane affording 0.473 g (73%yield) of product. This was dissolved inl mL of dichloromethane and 1.24 mL of 1M HCl/ether was added. The suspension was stirred for 30 minutes, filtered and washed with ether affording 0.47 g of compound 3. (mass spec. M+l = 457, MP = 188 - 194°C)
Example 5 (Compound 2)
Figure imgf000038_0001
A mixture of 0.7 g (1.67 mmol) of sulfoxide 10 from Example 3 and 0.84 g
(8.4 mmol) of 4-aminotetrahydropyran in 1 mL of NMP was stirred at 10 minutes. The reaction was exothermic and completed in 10 minutes. The mixture was diluted with water and extracted with ethyl acetate. The organic solution was washed with brine and dried (MgSO4) and removed in vacuo. The purification was done by column chromatography with silica eluting with 60% ethyl acetate in hexanes affording 0.46 g (73% yield) of product. This solid in 1 mL of dichloromethane was mixed with 1.45 mL of 1M HCl/ether and the mixture was stirred for 1 hour. Solvent was removed in vacuo affording 0.48g of compound 2. (mass spec. M+l = 380, MP = 211 - 214°C)
Example 6 (Compound 5)
Figure imgf000038_0002
Preparation of 4-aminotetrahvdrothiopyran-dioxide Step l 4-aminotetrahydrothiopyran
Figure imgf000039_0001
16 17 A suspension mixture of 5 g (0.043 mole) of tetrahydrothiopyran-4-one 16,
29.26 g (0.215 mole) of sodium acetate trihydrate and 14.9 g (0.215 mole) of hydroxylamine hydrochloride in 200 mL of ethanol was heated to reflux for six hours until reaction was completed. The reaction mixture was cooled and ethanol was removed under reduced pressure. The residue was diluted with 400 mL of ice water and was extracted with ethyl acetate, 3 X 150 mL. The organic solution was washed with brine, dried and filtered. The filtrate was concentrated under reduced pressure affording 5.6 g (quantitative yield) of the thianone oxime 77 (white solid).
Step 2
Figure imgf000039_0002
17 18
To 76 mL of 1M LAH7THF (0.076 mole) was added dropwise a solution of 2 g (0.015 mole) of thianone oxime 77 in 30 mL of THF. After addition was completed, the mixture was stirred under reflux for 7 hours and then at room temperature overnight. The suspension was cooled and 2.9 mL of water was added dropwise cautiously, followed by 2.9 mL of 15% aq. sodium hydroxide and then 8.7 mL of water. The suspension was stirred for 30 min., filtered over Celite and washed with 200 mL of ethyl acetate. The filtrate was dried, filtered and evaporated to dryness under reduced pressure (< 50°C) affording 1.62 g (92.3 % yield) of the 4-aminotetrahydrothiopyran 75. Step 3
Figure imgf000040_0001
To a suspension of 2.3 g (0.0197 mole) of the 4-aminotetrahydrothiopyran
18 in 25 mL of IN NaOH was added dropwise at 5°C 3.14 mL (3.75 g, 0.022 mole) of benzylchloroformate. Solid formed immediately and after addition was completed, the mixture was stirred at room temperature for 1 hour, filtered and washed with water. This was followed by washing with hexane (50 mL). After drying (air dried), 4.4 g (88% yield) of product 19 was obtained, (mass spec. M+l = 252).
Step 4
Figure imgf000040_0002
To a solution of 40 g (0.159 mole) of sulfide 19 in 200 mL of dichloromethane at room temperature was added in small portions of 75 g (0.33 mole) of 3-chloroperbenzoic acid. Reaction was exothermic. The reaction mixture was allowed to stir overnight. The mixture was washed with aqueous saturated Na2SO3 (2 X 150 mL) and then with NaHCO3 (3 XI 50 mL). The organic solution was then washed with brine and dried over MgSO4. The mixture was filtered and the filtrate was evaporated in vacuo to afford 37.5 g of the sulfone 20 (83% yield). Step 5
Figure imgf000041_0001
20 21
To a mixture of 10 g (0.026 mole) of the N-benzoyloxycarbonyl-sulfone 20 in 150 mL of ethanol in a Parr bottle was added 0.5 g of palladium hydroxide (20% on Carbon, Pearlman's catalyst). This was subjected to the Parr hydrogenator at 50 psi for 15 hours until completion. This was filtered over Celite and concentrated in vacuo affording 5.0 g of the free amine 27 (68% yield). Step 6
A mixture of 1.4 g (0.41 mmol) of sulfoxide 10 and 1.22 g (8.2 mmol) of 4- aminotetrahydrothiopyran-dioxide 27 in 3 mL of NMP was heated to 70°C for 2 hours. The mixture was cooled, diluted with water and extracted with ethyl acetate (2 X 75 mL). The combined ethyl acetate solution was washed with water (3 X 75 mL), brine and dried (MgSO4) and the crude material was purified by column chromatography with silica eluting with 4% methanol in dichloromethane affording 1.5 g of desired product. This was dissolved in 3 mL of dichloromethane and 4.5 mL of 1M HCl/ether was added dropwise. The suspension was stirred for 30 minutes and the solid was filtered and washed with ether affording 1.86 g (98% yield) of compound 5, (mass spec. M+l = 428, MP = 221.8 - 226.8°C). Example 7 (Compound 6)
Figure imgf000042_0001
A mixture of 0.4 g (1.2 mol) of sulfoxide 10 and 0.52 g (5.8 mmol) of 2- amino-2-methyl-l-propanol in 10 ml of chloroform and 0.8 ml of nmp was heated to 70°C for 3 hours. The chloroform was removed under reduced pressure. 40 ml of methanol/ether (1:1) was added. The suspension was stirred for 10 minutes and was filtered. The solid was washed with more ether affording 0.258g (58.5%yield) of desired product. This was dissolved in 15 ml of 10% methanol in dichloromethane and 0.85 ml of 1M HCl/ether was added. The mixture was stirred for 30 minutes and concentrated. Ether was added and the solid was filtered and washed with ether affording 0.295 g of compound 6. (mass spec. M+l = 368, MP =
Figure imgf000042_0002
Example 8 (Compound 7)
Figure imgf000042_0003
A glass sealed-tube (teflon screw cap) reactor was charged with 0.4 g (1.2 mmol) of the sulfoxide 10. This was purged with nitrogen for 2 minutes as the reaction vessel was cooled with an ice-water bath. 5 ml of isopropyl amine was added and the tube was sealed. The red solution was heated in a 64°C oil bath for 2 hours until reaction was completed. The mixture was cooled and the reaction vessel was rinsed with dichloromethane. The solvent was removed in vacuo and the sample was purified by column chromatography with silica eluting with a gradient of 5 to 10% ethyl acetate in dichloromethane affording 0.34 g (87% yield) of product. This light yellow solid was dissolved in a minimum amount of dichloromethane and 1.2 ml of IM HCl/ether was added, followed by 5 ml of ether. The yellow suspension was stirred for 1 hour and was filtered and washed with ether affording 0.34 g of compound 7. (Mass Spec. M+l = 338, MP = 210 -
212.5°C)
Example 9 (Compound 8)
Figure imgf000043_0001
A mixture of 0.4 g (1.2 mmol) of sulfoxide 10 and 0.29 g (2.33 mmol) of 4- fluorobenzylamine in 5 mL of chloroform was heated in a 60°C oil bath for 1.5 hours until reaction was completed. The product was purified directly by column chromatography eluting with a gradient of 5 to 10% ethyl acetate in dichloromethane affording 0.42 g (89% yield) of the product. The yellow solid was dissolved in a minimum amount of dichloromethane, and 1.25 mL of IM HCl/ether was added. The mixture was stirred for 30 minutes and solvent was removed in vacuo. Ether was added and the solid was filtered and washed with ether affording 0.469 g of compound 8. (mass spec. M+l = 404, MP = 178 - 180°C)
Example 10 (Compound 9)
Figure imgf000043_0002
A mixture of 0.4 g (1.2 mmol) of sulfoxide 10 and 0.36 g (2.4 mmol) of 2- aminoethyl methyl sulfone in 3 mL of NMP was heated to 65°C for 30 minutes. [2- aminomethyl sulfone was prepared by reacting 4-methoxybenzylamine with methyl vinyl sulfone in presence of triethylamine in THF at room temperature, the N- benzyl group was removed by stirring in methanol in presence of ammonium formate and 10%Pd-C ]. The mixture was cooled, diluted with water and ethyl acetate. The solid formed was filtered, washed with more ethyl acetate and then 40 mL of methanol affording 0.34 g (72.6% yield) of product. This was dissolved in 5 mL of 10% methanol in dichloromethane and 1 mL of IM HCl/ether was added. Stirring was continued for 30 minutes and solvent was removed in vacuo. Ether was added for trituation and the solid formed was filtered and washed with additional 10 mL of ether affording 0.374 g of compound 9. (mass spec. M+l = 402, MP = 172.2 - 176°C)
Example 11 (Compound 10)
Figure imgf000044_0001
Step l
Figure imgf000044_0002
22
A mixture of 2.48 g (10.1 mmol) of aldehyde 4_ from example 2, 1.83 g (12 mmol) of 4-fluorophenoxyacetonitrile (prepared from 4-fluorophenol and iodoacetonitrile in K CO3/DMF) and 7g (50.6 mmol) of potassium carbonate in 30 mL of NMP was heated at 110°C for 4 hours until the reaction was completed. The mixture was poured into 200 ml of water and extracted with ethyl acetate (3 X 125 mL). The organic solvent was washed with water (3 X 150mL), brine, diluted with 200 mL of hexanes, dried (MgSO4) and filtered through a short plug of silica. The solvent was removed in vacuo . Residual solid was purified by column chromatography with silica eluting with a gradient of 5% to 20% ethyl acetate in dichloromethane, affording 1.3 g of the aminopyridopyrimidine 22, (37% yield), (mass spec. M+l = 379, MP = 186.2 - 192.9°C) Step 2 "chloroacetaldehyde"
Figure imgf000045_0001
Figure imgf000045_0002
22 23
To a mixture of 1.3 g (3.4 mmol) of amine 22, 1.54 g (2.1 mL, 15.3 mmol) of triethylamine, 3 mL of water and 30 mL of acetonitrile was added a total of 2.4 mL (19.6 mmol, 5.8 eq) of 1,2-dichloroethyl ethyl ether over a period of 6 hours (1 equivalent/hour the first two hours and 0.5 equivalent/hour the following four hours), until the reaction was completed. The mixture was allowed to stand overnight at room temperature, diluted with water and extracted with ethyl acetate (2 X 100 mL). The organic solution was washed with brine and dried (MgSO4) and removed in vacuo. Purification was done by column chromatography with silica eluting with 10% ethyl acetate in hexanes affording 0.78 g (57% yield) of the phenoxy-tricyclic-imidazole 23 (57% yield). Step 3
Figure imgf000045_0003
24
23
To a cooled solution of 0.77 g (1.92 mmol) of the sulfide 23 in 30 mL of dichloromethane at 5°C was added 0.43 g (1.92 mmol) of 3-chloroperbenzoic acid (77% max.). The reaction was completed in 1 hour and the mixture was poured into cold saturated aqueous NaHCO3 and extracted with dichloromethane. The organic solution was washed with brine and dried (MgSO4). After removal of solvent in vacuo, 0.763 g of the sulfoxide was recovered (95% yield).
Step 4
A mixture of 0.4 g (0.96 mmol) of sulfoxide 24 and 0.48 g (4.78 mmol) of 4-aminotetrahydropyran in 1 mL of NMP was heated at 60 to 70°C for 30 minutes. The mixture was diluted with water and extracted with ethyl acetate. The organic solution was washed with brine and dried (MgSO4) and removed in vacuo. The purification was done by column chromatography with silica eluting with a gradient of 10 to 30% ethyl acetate in dichloromethane to elute out the non-polar impurities and finally with 2.5% methanol in dichloromethane to elute out the product, 0.210 g (58% yield). This solid in 1 mL of dichloromethane was mixed with 0.83 mL of IM HCl/ether and the mixture was stirred for 1 hour, diluted with ether and filtered affording 0.21g of compound 10. (mass spec. M+l = 380, MP = 198 - 206°C) Example 12 (Compound 11)
Figure imgf000046_0001
To 0.11 g (1.0 mmol) of 4-fluoroaniline in 5 ml of dichloromethane at 5°C was added 0.5 ml (1.0 mmol) of trimethylaluminum reagent (2M/toluene) dropwise. After addition, stirring was continued for 10 minutes. This solution was then added through a syringe to a solution of 0.355 g (0.85 mmol) of sulfoxide from Example 10 in 10 ml of dichloromethane at 5°C. The mixture was then stirred at 17 hours and then at reflux for 3 hours. This was poured into saturated aqueous NH4CI solution. The mixture was filtered and the filtrate was transferred to a separatory funnel as the layers were separated. The aqueous layer was extracted once more with dichloromethane and the combined organic solution was washed with brine and dried (brine, MgSO4). After removal of solvent in vacuo, the residue was purified by column chromatography with silica eluting with 10% ethyl acetate in dichloromethane affording 0.16 g of yellow solid. This was mixed with 5 ml of 20% methanol in dichloromethane and 0.49 ml of IM HCl/ether was added. This was stirred for 30 minutes and solvent was evaporated to dryness. 10 ml of ether was added and the yellow suspension was stirred for 10 minutes, filtered and washed with additional ether affording 0.145 g of compound 11. (mass spec. M+l = 390, mp = 289.3 - 291.1°C)
One of skill in the art will understand that certain modifications to the above schemes are contemplated and within the scope of the present invention. For example, certain steps will involve the use of protecting groups for functional groups that are not compatible with particular reaction conditions.
Example 13 The following are representative pharmaceutical formulations containing a compound of Formula (I).
Tablet formulation The following ingredients are mixed intimately and pressed into single scored tablets.
Quantity per Ingredient tablet, mg compound of this invention 400 cornstarch 50 croscarmellose sodium 25 lactose 120 magnesium stearate 5
Capsule formulation The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.
Quantity per Ingredient capsule, mg compound of this invention 200 lactose, spray-dried 148 magnesium stearate 2 Suspension formulation The following ingredients are mixed to form a suspension for oral administration.
Ingredient Amount compound of this invention 1.0 g fumaric acid 0.5 g sodium chloride 2.0 g methyl paraben 0.15 g propyl paraben 0.05 g granulated sugar 25.5 g Sorbitol (70% solution) 12.85 g
Veegum K (Vanderbilt Co.) 1.0 g flavoring 0.035 ml colorings 0.5 mg distilled water q.s. to 100 ml
Injectable formulation The following ingredients are mixed to form an injectable formulation.
Ingredient Amount compound of this invention 0.2 g sodium acetate buffer solution, 0.4 M 2.0 ml
HC1 (IN) or NaOH (IN) q.s. to suitable pH water (distilled, sterile) q.s. to 20 ml
All of the above ingredients, except water, are combined and heated to 60-70 °C with stirring. A sufficient quantity of water at 60 °C is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. to 100 g. Suppository formulation A suppository of total weight 2.5 g is prepared by mixing the compound of the invention with Witepsol® H-15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:
compound of the invention 500 mg
Witepsol® H-15 balance
Example 14 Inhibition Of ρ-38 (MAP) Kinase-Z/i Vitro Assay
The p-38 MAP kinase inhibitory activity of compounds of this invention in vitro was determined by measuring the transfer of the γ-phosphate from γ- P- ATP by p-38 kinase to Myelin Basic Protein (MBP), using the a minor modification of the method described in Ahn, N. G.; et al. J. of Biol. Chem. Vol. 266(7), 4220- 4227, (1991)
The phosphorylated form of the recombinant p38 MAP kinase was expressed with SEK-1 and MEK-K in E. Coli (see, Khokhlatchev, A. et al. J. of Biol. Chem. Vol. 272(17), 11057-11062, (1997) and then purified by affinity chromatography using a Nickel column. The phosphorylated p38 MAP kinase was diluted in kinase buffer (20 mM
3-(N-morpholino)propanesulfonic acid, pH 7.2, 25 mM β-glycerol phosphate, 5 mM ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid, ImM sodium vanadate, ImM dithiothreitol, 40mM magnesium chloride). Test compound dissolved in DMSO or only DMSO (control) was added and the samples were incubated for 10 min. at 30 °C. The kinase reaction was initiated by the addition of a substrate cocktail containing MBP and γ-33P-ATP. After incubating for an additional 20 min. at 30 °C, the reaction was terminated by adding 0.75% phosphoric acid. The phosphorylated MBP was then separated from the residual γ-33P-ATP using a phosphocellulose membrane (Millipore, Bedfrod, MA) and quantitated using a scintillation counter (Packard, Meriden, CT).
The p-38 inhibitory activities (expressed as IC50, the concentration causing 50% inhibition of the p-38 enzyme being analyzed) of the compounds listed in Table 1 in the specification are between 0.001 μM and 10 μM. For example, Table 2, below, shows representative values for inhibition of p38 using the Ex. 14 assay:
Figure imgf000050_0001

Claims

Claims
1. A compound represented by formula I:
Figure imgf000051_0001
(I) wherein:
Z is N or CH;
Z1 is selected from N and CH when the bond between atoms C5 and Z1 is a single bond, and Z1 is C when the bond between C5 and Z1 is a double bond; R1 is hydrogen or alkyl; R2 is alkyl, hydroxyalkyl, optionally-substituted aralkyl, optionally- substituted cycloalkyl, heteroalkyl, optionally-substituted heterocyclyl, optionally- substituted aryl, or optionally-substituted heteroaryl;
A is absent or -O-, -S(O)n- -CHR'-, -C(=O)-, or -NR3-, wherein n is 0, 1, or 2, R' is hydrogen or alkyl, and R is hydrogen, alkyl, optionallysubstituted aryl, optionallysubstituted heteroaryl, or optionallysubstituted cycloalkyl; the bond between atoms C5 and Z1 is a single or double bond; the bond between atoms C8 and C9 is a single or double bond; and Y is an alkyl, heteroalkyl, optionally-substituted cycloalkyl, optionally- substituted aryl, or optionally-substituted heteroaryl; or isomers, pharmaceutically acceptable salts, esters or prodrugs thereof.
2. A compound according to Claim 1, having the formula:
Figure imgf000051_0002
(I) wherein: R2 is selected from optionally-substituted aralkyl, optionally-substituted cycloalkyl, optionally-substituted heterocyclyl, optionally-substituted aryl, and . 4alkyl optionally substituted with one of hydroxy,
Figure imgf000052_0001
or S(O)2(Cι-4alkyl);
A is absent or -O-; Y is phenyl optionally substituted with one to two groups selected from halo, hydroxy, amino, alkyl or heteroalkyl; or isomers, pharmaceutically acceptable salts, esters or prodrugs thereof.
3. A compound according to Claim 2, wherein R2 is selected from cyclopentyl, cyclohexyl, tetrahydropyranyl, piperidinyl, thianonyl, tetrahydro-1,1- dioxide-2-H-thiopyranyl, phenyl, and benzyl, wherein each of said R2 groups is optionally-substituted with one of hydroxy, halogen, O(Cι-4alkyl), or S(O)2(Cι- 4alkyl); or R is selected from Cι-4alkyl optionally substituted with one of hydroxy,
O(Cι-4alkyl) or S(O)2(Cι-4alkyl).
A compound according to Claim 2 having the formula,
Figure imgf000052_0002
wherein R is as defined in claim 2.
5. A compound according to Claim 4, wherein R2 is selected from cyclopentyl, cyclohexyl, tetrahydropyranyl, piperidinyl, thianonyl, tetrahydro-1,1- dioxide-2-H-thiopyranyl, phenyl, and benzyl, wherein each of said R groups is optionally-substituted with one of hydroxy, halogen, O(CH3), or S(O)2(CH3); or R2 is selected from C]- alkyl optionally substituted with one of hydroxy, O(CH3) or S(O)2(CH3).
6. A compound according to Claim 1, wherein Z is -N-
7. A compound according to Claim 1 or 6, wherein Z1 is -C- and the bond between Z1 and C5 is a double bond.
8. A compound according to any one of Claims 1, 6 or 7, wherein A is absent or -O-.
9. A compound according to any one of Claims 1, 6-8, wherein R1 is hydrogen.
10. A compound according to any one of Claims 1, 6-9, wherein R2 is selected from cyclopentyl, cyclohexyl, tetrahydropyranyl, piperidinyl, thianonyl, tetrahydro-l,l-dioxide-2-H-thiopyranyl, phenyl, and benzyl, wherein each of said R groups is optionally-substituted with one of hydroxy, halogen, O(Cι-4alkyl), or S(O) (Cι-4alkyl); or R2 is selected from Cι-4alkyl optionally substituted with one of hydroxy, O(Cι-4alkyl) or S(O)2(Cι-4alkyl).
11. A compound according to any one of Claims 1, 6-10, wherein Y is phenyl optionally substituted with halo, hydroxy, amino, alkyl or heteroaryl.
12. A compound having the formula la,
Figure imgf000053_0001
la wherein Y is aryl; Z is N or CH; A is absent or O; R1 is hydrogen;
R2 is alkyl, hydroxyalkyl, optionally-substituted cycloalkyl, optionally-substituted heteocyclyl, optionally-substituted aryl, or optionally-substituted aralkyl; and the bond between C8 and C9 is a single or double bond.
13. The compound according to Claim 12, wherein Z is N, A is -O- and the bond between C8 and C9 is a double bond.
14. A compound according to claim 13 wherein: R2 is 4-tetrahydropyranyl and Y is 4-fluorophenyl; or R2 is 4-fluorophenyl and Y is 4-fluorophenyl.
15. A compound according to Claim 12, wherein Z is N, A is absent, and the bond between C8 and C9 is a double bond.
16. A compound according to Claim 15, wherein:
R2 is 4-hydroxycyclohexyl and Y is 2-chlorophenyl;
R2 is 4-tetrahydropyranyl and Y is 2-chlorophenyl; R is 4-(N-methyl-sulfonylpiperdinyl) and Y is 2-chlorophenyl;
R2 is cyclopentyl and Y is 2-chlorophenyl;
R2 is 4-(N-methyl-sulfonylpiperdinyl) and Y is 2-chlorophenyl;
R2 is 4-tetrahydro,l,l-dioxide-2-H-thio yranyl and Y is 2-chlorophenyl;
R2 is isopropyl and Y is 2-chlorophenyl; or R2 is 4-fluorbenzyl and Y is 2-chlorophenyl.
17. A compound according to Claim 1, having the formula
Figure imgf000054_0001
18. A compound according to Claim 17, wherein Z is N, A is absent, R1 is hydrogen, Y is 2-chlorophenyl, and R2 is 4-hydroxycyclohexyl.
19. A compound according to Claim 1, having the formula 1(c):
Figure imgf000055_0001
20. A compound according to Claim 19, wherein Z is N, A is absent, R1 is hydrogen, Y is 2-chlorophenyl, and R is 4-hydroxycyclohexyl.
21. A pharmeutical composition comprising a therapeutically effective amount of one or more compounds according to any one of claims 1-18 or 24 in combination with a pharmaceutically acceptable carrier.
22. A process of making a compound according to Claim 1, comprising: reacting a compound of formula A with a cyanide of formula CN-CH2-A-Y wherein A, Z and Y are as defined in Claim 1, and Rp is selected from lower alkyl and benzyl, to afford a compound of formula B;
Figure imgf000055_0002
b) treating compound B with a reagent selected from triethylamine, trialkylamine base, l,4-diazabicyclo[2.2.2]octane, or disopropylethylamine, and 1,2-dichloro- ethylether to obtain compound C;
Figure imgf000055_0003
c) oxidizing compound C with a reagent selected from 3-chloroperbenzoic acid, hydrogen peroxide/formic acid, hydrogen peroxide/methyltrioxorhenium VII, or OXONE, to obtain compound D; and
Figure imgf000056_0001
D
1 1 d) contacting compound D with an amine of formula -H2N-R R wherein R and R2 are as defined in claim 1 for a sufficient period of time to obtain the compound according to Claim 1.
23. A process of preparing a compound according to Claim 1 comprising: a) reacting a compound of formula E wherein Z, A and Y are as defined in Claim 1 and Rp is lower alkyl or benzyl, with a reagent selected from triphenylphosphine, diethylazodicarboxylate, and N-(2-hydroxyethyl)-phthalimide to obtain compound F;
Figure imgf000056_0002
b) reacting compound F with a hydrazine to obtain compound G;
Figure imgf000056_0003
G c) reacting compound G with trimethylaluminum to obtain compound H;
Figure imgf000057_0001
H d) optionally oxidizing compound H with a reagent selected from 3- chloroperbenzoic acid, hydrogen peroxide/formic acid, hydrogen peroxide/ methyltrioxorhenium VII, or OXONE, to obtain the corresponding sulfoxide and contacting the sulfoxide with an amine of formula -H2N-R!R2 wherein R1 and R2 are as defined in claim 1 for a sufficient period of time to obtain the compound according to Claim 1.
24. A compound as claimed in any one of claims 1-20 whenever prepared by a process as claimed in claim 22 or 23.
25. A compound as claimed in any one of claims 1-20 or 24 as a medicament.
26. A method for treating a p38 mediated disorder comprising administering to a patient in need of such treatment an effective amount of a compound according to any one of claims 1-20 or 24.
27. The method of Claim 26, wherein the p38 mediated disorder is selected from the group consisting of arthritis, Crohn's disease, Alzeihmer's disease, irritable bowl syndrome, adult respiratory distress syndrome, and chronic obstructive pulmonary disease.
28. Use of a compound as claimed in any one of claims 1-20 or 24 for the preparation of a medicament for treating a p38 mediated disorder.
29. The use of Claim 28, wherein the p38 mediated disorder is selected from the group consisting of arthritis, Crohn's disease, Alzeihmer's disease, irritable bowl syndrome, adult respiratory distress syndrome, and chronic obstructive pulmonary disease.
30. The invention as hereinbefore described.
***
PCT/EP2003/003178 2002-04-03 2003-03-27 Imidazo fused compounds WO2003082871A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002479644A CA2479644A1 (en) 2002-04-03 2003-03-27 Imidazo fused compounds
MXPA04009585A MXPA04009585A (en) 2002-04-03 2003-03-27 Imidazo fused compounds.
AU2003215675A AU2003215675B2 (en) 2002-04-03 2003-03-27 Imidazo fused compounds
EP03745276A EP1492790A1 (en) 2002-04-03 2003-03-27 Imidazo fused compounds
JP2003580336A JP2006503802A (en) 2002-04-03 2003-03-27 Imidazo condensation compounds
KR1020047015609A KR100656205B1 (en) 2002-04-03 2003-03-27 Imidazo fused compounds
BR0308937-1A BR0308937A (en) 2002-04-03 2003-03-27 Fused imidazo compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36992902P 2002-04-03 2002-04-03
US60/369,929 2002-04-03

Publications (1)

Publication Number Publication Date
WO2003082871A1 true WO2003082871A1 (en) 2003-10-09

Family

ID=28675587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/003178 WO2003082871A1 (en) 2002-04-03 2003-03-27 Imidazo fused compounds

Country Status (13)

Country Link
US (4) US6949560B2 (en)
EP (1) EP1492790A1 (en)
JP (1) JP2006503802A (en)
KR (1) KR100656205B1 (en)
CN (1) CN1293078C (en)
AR (1) AR039219A1 (en)
AU (1) AU2003215675B2 (en)
BR (1) BR0308937A (en)
CA (1) CA2479644A1 (en)
MX (1) MXPA04009585A (en)
PL (1) PL374544A1 (en)
RU (1) RU2310657C2 (en)
WO (1) WO2003082871A1 (en)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021551A1 (en) * 2003-08-27 2005-03-10 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2008506673A (en) * 2004-07-15 2008-03-06 サノフイ−アベンテイス Pyrido-pyrimidine derivatives, their preparation, their therapeutic use for cancer treatment
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2018153373A1 (en) * 2017-02-27 2018-08-30 贝达药业股份有限公司 Fgfr inhibitor and application thereof
CN109721600A (en) * 2017-10-30 2019-05-07 如东凌达生物医药科技有限公司 A kind of nitrogenous fused ring compound and its preparation method and application
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3476846A4 (en) * 2016-06-28 2019-11-20 Hanmi Pharmaceutical Co., Ltd. Novel heterocyclic derivative compound and use thereof
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11091485B2 (en) 2017-05-23 2021-08-17 Shengke Pharmaceuticals (Jiangsu) Ltd. Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound as protein kinase inhibitor
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
WO2022032071A1 (en) * 2020-08-07 2022-02-10 Abm Therapeutics Corporation Kinase inhibitors and uses thereof
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3845534A4 (en) * 2018-08-27 2022-04-06 Betta Pharmaceuticals Co., Ltd Salt form and crystal form of novel azatricyclic compound and use thereof
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2022-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008114119A2 (en) * 2007-03-20 2008-09-25 Cadila Pharmaceuticals Limited P38 inhibitors
EP2768506A4 (en) * 2011-10-21 2015-08-19 Glaxosmithkline Llc Compounds and methods for enhancing innate immune responses
CN105481858B (en) * 2014-10-11 2019-05-17 上海医药集团股份有限公司 A kind of nitrogenous fused heterocyclic compound, preparation method, composition and application
CA3003433A1 (en) 2015-10-27 2017-05-04 Children's Hospital Medical Center Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2018004258A1 (en) * 2016-06-28 2018-01-04 한미약품 주식회사 Novel heterocyclic derivative compound and use thereof
ES2968252T3 (en) * 2016-11-16 2024-05-08 Impact Therapeutics Shanghai Inc Compound 8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ketone
JP7041821B2 (en) * 2017-10-30 2022-03-25 シャンハイ リンジーン バイオファーマ カンパニー リミテッド Amino-substituted nitrogen-containing condensed ring compound, its preparation method and use
WO2020038458A1 (en) * 2018-08-23 2020-02-27 如东凌达生物医药科技有限公司 Class of fused ring triazole compound, preparation method, and use
CN113646314B (en) * 2019-03-08 2023-12-08 首药控股(北京)股份有限公司 FGFR4 kinase inhibitor and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029042A1 (en) * 1999-10-21 2001-04-26 F. Hoffmann-La Roche Ag Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
WO2002018380A1 (en) * 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522947A (en) * 1982-03-29 1985-06-11 Usv Pharmaceutical Corporation Certain 1,3-oxazolo[4,5H]quinolines useful as anti-allergy agents
US4656281A (en) * 1983-03-18 1987-04-07 Usv Pharmaceutical Corp. Imidazo quinoline compounds useful as anti-allergy agents
DE3502689A1 (en) * 1985-01-26 1986-07-31 Hoechst Ag, 6230 Frankfurt ELECTROPHOTOGRAPHIC RECORDING MATERIAL
US4831040A (en) * 1988-02-01 1989-05-16 Rorer Pharmaceutical Corporation Method of prevention and treatment of peptic ulcers
GB9123916D0 (en) 1991-11-11 1992-01-02 Wellcome Found Heterocyclic compounds
JPH11292878A (en) 1998-04-09 1999-10-26 Yamanouchi Pharmaceut Co Ltd Imidazonaphthylidine derivative
HU229604B1 (en) 2001-02-12 2014-02-28 Hoffmann La Roche 6-substituted pyrido-pyrimidines, process for their preparation and pharmaceutical compositions containing them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029042A1 (en) * 1999-10-21 2001-04-26 F. Hoffmann-La Roche Ag Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
WO2002018380A1 (en) * 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021551A1 (en) * 2003-08-27 2005-03-10 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2008506673A (en) * 2004-07-15 2008-03-06 サノフイ−アベンテイス Pyrido-pyrimidine derivatives, their preparation, their therapeutic use for cancer treatment
US10213427B2 (en) 2010-12-22 2019-02-26 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10813930B2 (en) 2010-12-22 2020-10-27 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10131667B2 (en) 2012-06-13 2018-11-20 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11840534B2 (en) 2012-06-13 2023-12-12 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9745311B2 (en) 2012-08-10 2017-08-29 Incyte Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US11530214B2 (en) 2013-04-19 2022-12-20 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10040790B2 (en) 2013-04-19 2018-08-07 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10947230B2 (en) 2013-04-19 2021-03-16 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US10450313B2 (en) 2013-04-19 2019-10-22 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11014923B2 (en) 2015-02-20 2021-05-25 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10016438B2 (en) 2015-02-20 2018-07-10 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10251892B2 (en) 2015-02-20 2019-04-09 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11667635B2 (en) 2015-02-20 2023-06-06 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10632126B2 (en) 2015-02-20 2020-04-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9801889B2 (en) 2015-02-20 2017-10-31 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10738048B2 (en) 2015-02-20 2020-08-11 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10214528B2 (en) 2015-02-20 2019-02-26 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3476846A4 (en) * 2016-06-28 2019-11-20 Hanmi Pharmaceutical Co., Ltd. Novel heterocyclic derivative compound and use thereof
TWI741155B (en) 2017-02-27 2021-10-01 大陸商貝達藥業股份有限公司 FGFR inhibitor and its application
US11365196B2 (en) 2017-02-27 2022-06-21 Betta Pharmaceuticals Co., Ltd. FGFR inhibitor and application thereof
RU2745035C1 (en) * 2017-02-27 2021-03-18 Бетта Фармасьютикалз Ко., Лтд. Fgfr inhibitor and its application
WO2018153373A1 (en) * 2017-02-27 2018-08-30 贝达药业股份有限公司 Fgfr inhibitor and application thereof
EP3587419A4 (en) * 2017-02-27 2020-08-05 Betta Pharmaceuticals Co., Ltd. Fgfr inhibitor and application thereof
AU2018226315B2 (en) * 2017-02-27 2021-01-28 Betta Pharmaceuticals Co., Ltd. FGFR inhibitor and application thereof
US11091485B2 (en) 2017-05-23 2021-08-17 Shengke Pharmaceuticals (Jiangsu) Ltd. Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound as protein kinase inhibitor
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US10537560B2 (en) 2017-10-05 2020-01-21 Fulcrum Therapeutics. Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN109721600B (en) * 2017-10-30 2021-04-27 上海凌达生物医药有限公司 Nitrogen-containing fused ring compounds and preparation method and application thereof
CN109721600A (en) * 2017-10-30 2019-05-07 如东凌达生物医药科技有限公司 A kind of nitrogenous fused ring compound and its preparation method and application
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
EP3845534A4 (en) * 2018-08-27 2022-04-06 Betta Pharmaceuticals Co., Ltd Salt form and crystal form of novel azatricyclic compound and use thereof
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11866432B2 (en) 2018-10-11 2024-01-09 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
WO2022032071A1 (en) * 2020-08-07 2022-02-10 Abm Therapeutics Corporation Kinase inhibitors and uses thereof
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2022-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors

Also Published As

Publication number Publication date
US20030232847A1 (en) 2003-12-18
US20050197352A1 (en) 2005-09-08
PL374544A1 (en) 2005-10-31
CN1293078C (en) 2007-01-03
US7285559B2 (en) 2007-10-23
RU2310657C2 (en) 2007-11-20
AR039219A1 (en) 2005-02-09
JP2006503802A (en) 2006-02-02
US6949560B2 (en) 2005-09-27
MXPA04009585A (en) 2005-01-11
US7285561B2 (en) 2007-10-23
KR20040099384A (en) 2004-11-26
CN1646529A (en) 2005-07-27
AU2003215675A1 (en) 2003-10-13
AU2003215675B2 (en) 2007-07-12
RU2004132204A (en) 2005-11-20
US20060252783A1 (en) 2006-11-09
CA2479644A1 (en) 2003-10-09
US20060252784A1 (en) 2006-11-09
US7081462B2 (en) 2006-07-25
KR100656205B1 (en) 2006-12-12
EP1492790A1 (en) 2005-01-05
BR0308937A (en) 2005-01-04

Similar Documents

Publication Publication Date Title
AU2003215675B2 (en) Imidazo fused compounds
AU776250B2 (en) Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
EP1226144B1 (en) Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
US7439247B2 (en) Bicyclic pyridine and pyrimidine P38 kinase inhibitors
EP1919918A2 (en) P38 map kinase inhibitors and methods for using the same
EP1685131B1 (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
WO2004092144A2 (en) Quinazoline compounds useful as p38 kinase inhibitors
EP1620105B1 (en) (6-(phenoxy)-pyrido¬3,4-d|pyrimidin-2-yl)-amine derivatives as p38 kinase inhibitors for the treatment of inflammatory conditions such as rheumatoid arthritis
US20080146590A1 (en) P38 map kinase inhibitors and methods for using the same
JP4028236B6 (en) Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2479644

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003745276

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038075369

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/009585

Country of ref document: MX

Ref document number: 374544

Country of ref document: PL

Ref document number: 1020047015609

Country of ref document: KR

Ref document number: 2003215675

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003580336

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004132204

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020047015609

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003745276

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003215675

Country of ref document: AU